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ABSTRACT OF DISSERTATION 
 
 
 
 
STUDIES ON THE ROLE OF ACID SPHINGOMYELINASE AND CERAMIDE 
ON THE REGULATION OF TACE ACTIVITY AND TNF PRODUCTION BY 
MACROPHAGES 
 
 
Acid Sphingomyelinase (ASMase) activity has been proposed to mediate 
LPS signaling in various cell types. This study shows that in macrophages, 
ASMase is a negative regulator of LPS-induced TNF secretion. ASMase-
deficient (asm-/-) mice and isolated peritoneal macrophages produce several fold 
more TNF than their wild-type (asm+/+) counterparts when stimulated with LPS. 
The mechanism for these differences however is not transcriptional but post-
translational.  
The TNF converting enzyme (TACE) catalyzes the maturation of the 
26kD precursor (proTNF) to the active 17kD form (sTNF). In mouse peritoneal 
macrophages, the activity of TACE rather than the rate of TNF mRNA synthesis 
was the rate-limiting factor regulating TNF production. Substantial portion of the 
translated proTNF was not processed to sTNF; instead it was rapidly 
internalized and degraded in the lysosomes. TACE activity was 2 to 3 fold higher 
in asm-/- macrophages as compared to asm+/+ macrophages and was suppressed 
when cells were treated with exogenous ceramide and SMase. In asm-/- but not 
in asm+/+ macrophages, indirect immunofluorescence experiments revealed 
distinct TNF-positive structures in close vicinity of the plasma membrane. Asm-/- 
cells also had higher number of EEA1-positive early endosomes. Co-localization 
experiments that involved inhibitors of TACE and/or lysosomal proteolysis 
suggest that in asm-/- cells a significant portion of proTNF is sequestered within 
the early endosomes, and instead of undergoing lysosomal proteolysis it is 
recycled to the plasma membrane and processed to sTNF. 
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1 
CHAPTER ONE 
 
Introduction 
 
A. Regulation and biological effects of Tumor Necrosis Factor  in health 
and disease 
 
Tumor necrosis factor  (TNF)1 belongs to a class of proteins, called 
cytokines, which are important mediators in host response to stresses such as 
infection, inflammation, and injury. It is highly conserved among mammals with 
78% identity between human and mouse protein.  
Since it was identified more than 30 years ago, several thousand papers 
looking mostly at biological effects of TNF in variety of cell types and animal 
models have been published. TNF was initially described as a factor capable of 
killing tumor cells in vitro and of causing hemorrhagic necrosis of transplantable 
tumors in mice [1]. Later studies revealed that it has a broad spectrum of 
biological activities including stimulation of neutrophil adhesion and activation, 
chemotaxis, phagocytosis, and vascular permeability to name of few [2-5].   
                                                
1 Abbreviations: ADAM, A Disintegrin and metalloproteinase; ANOVA, 
Analysis of Variance; ASMase, Acid sphingomyelinase; AP-1, Activator protein-1; 
EEA1, Early endosomal antigen 1; ELISA, Enzyme-linked immunosorbent assay; 
ERK, Extracellular signal regulated kinase; FITC, Fluorescin isothiocyanate; 
HPLC, High pressure liquid chromatography; IL-1, Interleukin-1; i.p., 
intraperitoneally; IRAK, Interleukin-1 receptor-associated kinase; JNK, c-Jun 
terminal kinase; LBP, LPS binding protein, LPS, Lypopolysaccharide; MAPK, 
Mitogen-activated protein kinase; MyD88, Myeloid differentiation factor 88; NBD, 
6-((N-(7nitrobenz-2-oxa-1,3-diazol-4-yl))amino)-C6; NF-B, Nuclear factor B; 
NH4Cl, Ammonium chloride; NSMase, Neutral sphingomyelinase; PGE2, 
Prostaglandin E2; PMA, Phorbol 12 myristate 13 acetate; RA, Rheumatoid 
arthritis; RFU, Relative fluorescent units; SDS-PAGE, Sodium dodecyl sulfate 
polyacrylamide gel electrophoresis;  siRNA, Small inhibitory RNA; SM, 
sphingomyelin; SPT, serine palmitoyltransferase; S-1-P, sphingosine-1-
phosphate; TACE, TNF converting enzyme; TAK1, Transforming growth factor-
-activated kinase; TGF, Transforming growth factor ; TLR, Toll-like receptor; 
TNF, Tumor necrosis factor ; TRAF6, Tumor necrosis factor-associated factor; 
TRITC, Tetramethylrhodamine isothiocyanate. 
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Tissue and cellular effects of TNF 
 
TNF has a central role in the initial host response to infection and it is a 
key player in the regulation of immune homeostasis. Studies in TNF transgenic 
and TNF knockout mice have demonstrated that TNF has important 
immunomodulatory functions both in vivo and in vitro. It is required not only for 
the initial priming phase of antigen specific immunity and effector functions, but 
also for the resolution phase [6]. Furthermore, studies in TNF knockout mice 
show that TNF plays a critical role in germinal centers formation in the spleen 
[7]. These structures are important for antibodies isotype switching, affinity 
maturation and memory formation  thus linking TNF to the adaptive immunity. 
TNF also has diverse effects upon the neutrophil population ranging from 
stimulation of neutrophil release from bone marrow to regulation of neutrophil 
chemotaxis [4], degranulation [2], superoxide production [8], and lysozyme 
release [2]. TNF stimulates the phagocytic potential of macrophages and the 
production of a number of pro- and anti- inflammatory mediators such as IL-1, 
IL-6, PGE2, etc [9] [10]. 
TNF can induce a wide variety of biological effects and has a profound 
impact on the function of many cell types and tissues, which do not belong to the 
immune system. The incubation of endothelial cells with TNF increases 
vascular permeability [11]. Chronic delivery of TNF has been linked to the loss 
of total body protein and significant histologic changes within the liver [12]. 
Furthermore, in vivo studies indicated that sub-lethal doses of TNF affect the 
adipose tissue and elevate serum levels of triglycerides and free fatty acids [13, 
14]. 
 
Dysregulation of TNF and Diseases 
 
In a healthy state, TNF is produced in response to various stimuli mainly 
by macrophages. However, the onset of many diseases is correlated with the 
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induction of TNF production by various cells that normally do not produce it. 
Interestingly, however, the important questions of how it is regulated and what 
makes the difference between its beneficial and deleterious effect are not yet 
answered. Nevertheless, there are three major factors which appear to be of 
significant importance: concentration, duration and location, or combinations of 
them. 
TNF is not usually detectable in young and healthy individuals, but its 
levels sharply increase during inflammatory response. Importantly, its secretion is 
transient and TNF is quickly and efficiently cleared when the pathogen is 
neutralized. The importance of the strict regulatory mechanisms sensing and 
maintaining proper TNF levels is underlined by the observation that pathological 
dysregulation of TNF production/clearance occurs in many diseases.          
Uncontrolled systemic release of TNF is a hallmark of septic shock and it 
is tightly linked to the morbidity and mortality of the disease [15, 16]. Unlike 
systemic inflammation, TNF in rheumatoid arthritis (RA) is produced locally, but 
its secretion persists over a long period of time. Similarly, local but chronic 
production of TNF is implicated in the pathology of Crohn’s disease and 
asthma. The cause-effect relationship between TNF and the onset or the 
severity of the disease is supported by experimental data showing that 
overexpression of TNF in mice results in chronic inflammatory arthritis and 
inflammatory bowel disease [17, 18]. 
TNF is mostly discussed in the context of the innate immunity but it can 
also be produced by cells unrelated to the immune system, such as adipocytes, 
smooth and cardiac muscle cells, endothelial cells, osteoclasts, etc (Fig.1.1).  
Mounting evidence suggests that obesity promotes a state of chronic 
inflammation with elevation of TNF, which contributes to insulin resistance and 
type 2 diabetes. Although it is not entirely clear what the trigger of TNF 
production is for the prediabetic state, it might be nutritionally regulated. 
Dysregulation of TNF production and chronic inflammation are also a 
hallmark of physiologic process such as aging [19]. TNF is one of the prime 
signals inducing cellular apoptosis in muscle, and is therefore an important 
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contributor to muscle waste in the elderly [20, 21]. Elevated levels of TNF are 
also evident in a large number of neurological disorders including: traumatic brain 
injury, multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease; but 
whether TNF signaling actively contributes to, or limits neuronal injury in these 
disorders has yet to be established [22-25]. 
On certain occasions chronic elevation of TNF may prove beneficial in 
suppressing the active stage of a disease. For instance, the effects of TNF 
blockade, which is beneficial in a number of diseases has been assessed in 
individuals with multiple sclerosis and was found to worsen the disease [26, 27].  
Furthermore, immunosuppressive effects of TNF might explain the reports of 
rare demyelinating syndromes in patients after prolonged TNF blockade [28], as 
well as the development of  antinuclear antibodies and lupus syndromes in a 
significant proportion of patients with RA receiving anti-TNF therapy [29].  
At the cellular level, TNF activates NF-B, JNK, ERK, and caspases, 
which are part of signaling pathways leading to cell survival, proliferation, and 
apoptosis. It has been suggested that acute and chronic TNF responses may 
be determined at the biochemical level by the complex interactions between 
these pathways [30]. For example, TNF plays an important role in immune 
homeostasis including lymphocyte activation, survival, and differentiation. 
Inhibition of the caspase pathway by sustained activation of NF-B will generate 
a survival signal, which is critical for rapid immune responses to foreign 
pathogens.  On the other hand, inappropriate expansion of self-reactive 
lymphocyte population at sites of inflammation would clearly be detrimental. The 
factors which act as a switch between pro-survival and pro-apoptotic pathways 
still remain mostly unknown. However, a study in human fibroblasts points at NF-
B as such a factor, demonstrating that prolonged stimulation with TNF impairs 
IB re-synthesis, resulting in continued activation of NF-B response [31].  
 
B. Sphingolipids metabolism and biological effects 
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Sphingolipids are essential components of all biological membranes, but 
are also well-recognized active biomolecules which mediate and modulate 
diverse signaling pathways. Sphingosine is one of the first sphingolipids which 
was identified, and has been implicated in the regulation of cell cycle, 
cytoskeleton reorganization, endocytosis, and apoptosis [32]. Even more 
attention has been given to two other sphingolipids, ceramide and sphingosine-1-
phosphate (S-1-P), which often have antagonistic effects: ceramide regulates 
many cell-stress responses including apoptosis and cell senescence [33, 34], 
while S-1-P has a crucial role in cell survival and cell migration [35]. Among these 
bioactive sphinglipids, ceramide is produced in the largest amount and is 
considered the central molecule in sphingolipid biosynthesis and catabolism. The 
two main metabolic pathways for generation of ceramide are (i) the de novo 
synthesis in the endoplasmic reticulum, and (ii) the turnover of sphingomyelin 
(SM) either at the plasma membrane or in the endosomal/lysosomal 
compartment (Fig. 1.2). A number of agonists have been shown to activate these 
pathways leading to transient elevation in ceramide. The magnitude and 
temporal pattern of ceramide accumulation is further influenced by the activity of 
ceramidases, SM synthases, ceramide kinase, and glucosyl/galactosyl ceramide 
synthases.  These enzymes catalyze the conversion of ceramide to other 
sphingolipids, and some agonists seem to coordinately regulate both the 
ceramide production and turnover. 
The de novo pathway for synthesis of ceramide takes place in the 
endoplasmic reticulum and starts with condensation of palmitoyl-CoA and serine. 
This is the rate-limiting step catalyzed by serine palmitoyltransferase (SPT), 
which produces 3-ketosphinganine. Additional reactions of reduction followed by 
acylation generate relatively inactive dihydroceramide, which is converted by 
desaturase to the bioactive ceramide. The newly generated ceramide is actively 
transported to the Golgi apparatus, where it serves as a rate-limiting substrate in 
the synthesis of complex sphingolipids, like SM and glycosphingolipids. 
The alternative pathway for ceramide generation is the hydrolysis of 
sphingomyelin by a group of enzymes known as sphingomyelinases (SMases). 
SMase activities with neutral and acidic pH optima are found in most mammalian 
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cells, and an enzyme active in alkaline pH is localized in the intestinal wall. 
Currently, research is focused on 4 genes encoding different mammalian 
SMases: smpd1 encodes two forms of acidic SMase, one associated with the 
endosomal/lysosomal compartment (ASMase), and a second one found in the 
plasma and the conditioned medium of stimulated cells (SSMase). smpd2 and 
smpd3 encode the Neutral SMase 1 (nSMase1) and 2 (nSMase2), both of which 
are Mg2+-dependent but differ in their sub-cellular localization and role in 
signaling. The recently cloned smpd4, is suggested to encode a novel form of 
NSMase, nSMase3 that is found predominantly in skeletal muscle and heart. 
ASMase is a 72kD glycoprotein with a 57kD peptide core. The processing 
of the carbohydrate moieties within the Golgi is critical for sub-cellular trafficking 
of this enzyme. For example, the addition of mannose-6-phosphate residues is 
essential for lysosomal localization of ASMase. Alternative carbohydrate 
processing within the Golgi can result in targeting the enzyme to the secretory 
pathway [36, 37].  
ASMase was first purified from human brain, and was found to have 
optimal pH of 5.0 [38]. Based on trypsin digestion and mass spectrometric 
analysis a model was proposed, according to which the enzyme has three 
domains: an activator domain, followed by a proline rich domain, and a catalytic 
C-terminal domain. Both the lysosomal and the secretory forms require divalent 
cation Zn2+ for proper activity [36].  Many lipids were also found to influence 
ASMase activity. For example, the presence of fatty acids, mono-, di-, and tri-
acylglycerols as well as phosphatidylinositol has been found to activate ASMase 
and stimulate sphingomyelin hydrolysis [39]. On the other hand, ceramide-1-
phosphate, S-1-P, and phosphatidylinositol-4,5-bisphosphate inhibit ASMase [40, 
41]. Interestingly, cholesterol, which physically associates with sphingomyelin 
within lipid rafts, also inhibits ASMase [42]. Furthermore, the activation of 
ASMase leads not only to sphingomyelin hydrolysis but also cholesterol depletion 
[43]. Accordingly the loss of ASMase activity causes accumulation of both 
sphingomyelin and cholesterol.  
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ASMase is activated by numerous stimuli including TNF, LPS, 
Fas/CD95, radiation, and ischemia, and in a large variety of cell types [44-49] 
(Fig.1.3). In many cases, the activation of ASMase is associated with its 
translocation to the plasma membrane [50]. The cellular mechanisms regulating 
ASMase activity and localization remain unclear, although it has been suggested 
that phosphorylation of Ser508 is required for ASMase translocation to the plasma 
membrane after UV irradiation of MCF-7 cells [51]. Furthermore, Jin et al 
demonstrated that lysosomal trafficking and fusion with the plasma membrane is 
linked to the formation of lipid rafts in endothelial cells [50].  Lipid rafts have been 
implicated in receptor clustering and initiation of signal transduction via death 
receptors such as TNFR and CD95 [44, 46, 52]. Data coming from the inhibition 
of ASMase activity (using siRNA, or pharmacologic inhibitors or using NPD cells 
or knockout mice) have shown that this enzyme is indispensable for the 
execution of apoptotic response in variety of cell types. For instance, ASMase 
knockout mice were protected against endothelial apoptosis and had higher 
survival rate in response to LPS [53]. Furthermore, studies in fibroblasts from 
Niemann–Pick disease type A patients, who exhibit deficiency of ASMase and 
hepatocytes from ASMase knockout mice show that ASMase activation is 
required and sufficient for CD95 induced apoptosis [46]. ASMase is also 
important for tumor suppression and sensitivity to radiation therapy. Tumors 
growth progresses faster in ASMase knockout mice compared to the wild-type 
controls. 
  The hydrophobic nature of ceramide limits its diffusion in the water-based 
cellular environment, and therefore its action is limited to the location of its 
generation, mainly endolysosomes and lipid rafts. Only a few direct targets of 
ceramide have been described, which can potentially serve as mediators of its 
action. Lysosomal protease cathepsin D is one of them. After its activation by 
ASMase derived ceramide, the mature form of cathepsin D is released in the 
cytosol and triggers mitochondrial death pathway [54]. 
ASMase has an important role in pathogen infection and recovery. 
ASMase knockout mice easily succumb to infections with P. aeruginosa, L 
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monocytogenes, and alphaviruses [55, 56]. However, during bacterial or viral 
infections the role of ASMase is most likely linked to membrane reorganization 
and impact on internalization and vesicle fusion rather than modulation of 
signaling pathways. ASMase deficient cells are incapable of P.aeruginosa 
internalization and apoptosis, which are essential to clear the pathogen. The 
mechanism underlying high susceptibility of ASMase knockout mice to L. 
Monocytogenes revealed that a lack of ASMase activity leads to impaired phago-
lysosomal fusion, which is required for lysosomal degradation of the bacteria 
[57]. The role of ASMase activity in viral infections is very diverse. It appears to 
be important for the uptake of rhinoviruses as well as the infection and replication 
of herpes virus [58]. Ng et al demonstrated that after infection with Sindbis virus 
ASMase deficient cells produced more infectious virions compared to the control 
cells [59].   
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Figure 1.1. Summary of the stimuli activating TNF producing cells and 
subsequent biological effects initiated by TNF. 
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Figure 1.2. Metabolic pathways responsible for ceramide synthesis and 
degradation. The names of relevant subcellular organelles are shown in bold. 
Black solid arrows are used to depict metabolic conversions. Black dashed 
arrows indicate protein-mediated or vesicular transfer.  Abbreviations: ACDase, 
Acid Ceramidase; ASMase, Acid Spjingomyelinase; Cer, ceramide; C-1-P, 
ceramide-1-phosphate; dhCer, dihydroceramide; dhSph, dihydrosphingosine; 
NSMase2, neutral sphingomyelinase 2; SK, sphingosine kinase; SM, 
sphingomyelin; Sph, sphingosine; SMS, sphingomyelin synthase; SPPase, 
sphingosine phosphate phosphatase; SPT, serine palmitoyltransferase; SSMase, 
secretory sphingomyelinase 
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Figure 1.3. Agonists and signaling pathways for activation of Acid and 
Secretory sphingomyelinases. 
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CHAPTER TWO 
 
LPS-induced production of TNF by macrophages. In vivo and in vitro 
models to study the role of ASMase in LPS signaling 
 
A. Introduction 
 
Macrophages play a pivotal role in the production and regulation of TNF 
levels. TNF is one of the first pro-inflammatory cytokines secreted in response 
to bacterial infection and appears to mediate the majority of the symptoms seen 
in sepsis [60, 61]. The rate of TNF biosynthesis increases 1000 fold or more 
following stimulation with LPS, which makes it one of the most potent inducers of 
TNF production by macrophages [62]. 
LPS is a component of the outer membrane of gram-negative bacteria and 
is indispensable for the integrity of the bacterial membrane. It has been 
estimated that one bacterial cell contains approximately 3.5x106 LPS molecules, 
which occupy three-quarters of the bacterial surface [63].  LPS consists of 3 
components: lipid A, core oligosaccharide, and polysaccharide side chain (O-
specific chain). Lipid A is the active component recognized by the innate immune 
system [64].  
In the circulation, LPS is present in a complex with LPS binding protein 
(LBP). The recognition of LPS at the cell surface is required for the initiation of 
the transmembrane signal leading to cell activation, and involves at least 3 
proteins: CD14, MD-2, and TLR4. CD14 can exist as a soluble molecule, but is 
more often anchored to the plasma membrane by a glycosylphosphatidylinositol 
anchor. It facilitates the transfer of LPS from LBP to a TLR4/MD-2 receptor 
complex [65, 66]. MD-2 is an indispensable molecule in the LPS sensing 
complex and physically associates with the signaling receptor TLR4. 
Dimerization of the receptor initiates the signal transduction by the engagement 
of cytosolic adaptor proteins. MyD88-dependent signaling cascade is well-
studied and depends on the phosphorylation and proteosome-mediated 
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degradation of IRAK-1. This is crucial for the activation of downstream targets 
such as MAP kinases and transcription factors including NF-B, AP-1, Ets, and 
Elk-1 [67]. In vitro stimulation of macrophages with LPS results in a number of 
changes in the transcriptional and translational machinery of the cell, which favor 
the production and release of TNF. Transcription of the TNF gene leads to the 
production of a single mRNA product. The control of TNF-gene expression is 
mediated primarily by NF-B binding sites present within the TNF gene 
promoter [68-71], although the requirement of raf-1/MEK-1/2/ERK1/2 has been 
also suggested by number of studies [62, 72]. It has been found that treatment of 
cells with ERK inhibitor PD-098059 reduced TNF mRNA expression in a dose 
dependent manner and TNF secretion was completely abolished in the 
presence of Ro 09-2210, a MEK inhibitor, which blocks not only activation of 
ERK1/2, but also JNK and p38 [73]. Additional studies further supported the role 
of p38 activation for TNF production [74] and also suggested that JNK might be 
involved in the translational regulation of TNF [75]. Translational activation of 
TNF is dependent on a conserved element found within the 3’ untranslated 
regions [76]. Translation of mouse TNF mRNA produces the 26kD TNF 
precursor, which has 233 amino acids and undergoes post-translational 
glycosylation giving rise to several modified species which are susceptible to 
treatment with glycosylase inhibitors and contribute to the smear like pattern 
seen on a Western blot [77].  An additional form of sTNF with an estimated 
molecular weight of 19kDa has been observed and was shown to contain 
additional amino acids from the precursor protein as a result of different post-
translational processing [78]. Glycosylation of TNF has not been detected in 
human samples and its physiological importance in mouse is currently unknown. 
However, it was determined that it does not interfere with the biological activity of 
this cytokine in vitro [78]. 
The TNF precursor contains a highly conserved sequence of 79 amino 
acids at the N-terminus, which serves to anchor proTNF in the plasma 
membrane. The precursor is a type II membrane protein with 18 amino acids 
comprising the hydrophobic transmembrane region. The 26kD form is 
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proteolitically cleaved by the TNF converting enzyme (TACE) to give a 17kD 
active form. sTNF exists in solution as a homotrimer with a total molecular 
weight of 52KD. This is the form that binds to the TNF receptors and exerts its 
biological effects.  
 LPS also activates the secretory and lysosomal forms of Acid 
sphingomyalinase, one of the major ceramide producing enzymes. Importantly, 
accumulation of ceramide after LPS stimulation has been also reported and 
coincides with the peak of ASMase activity. ASMase is proposed to mediate 
many of the cellular effects of LPS, including the induction of apoptosis in 
endothelial cells, hepatic necrosis, etc [53]. Although the effects of ceramide on 
LPS-induced signaling molecules are various and often depend on the cell type, 
ASMase derived ceramide appears to play an important role as a modulator of 
LPS response. Whether ASMase affects TNF production is unclear, however 
such effect is likely because ASMase is proposed to mediate the activation of 
NF-B and JNK in response to other agonists.  
In humans, a genetic deficiency of ASMase results in autosomal recessive 
Niemann-Pick disease (NPD), which is further divided into type A and B based 
on clinical and pathological findings. Mutations in the ASMase gene cause an 
abnormal accumulation of sphingomyelin and in patients with the more severe 
form of the disease (type A) this affects the function of visceral organs and brain, 
and leads to lethality at early age. Fibroblasts from patients with NPDA are often 
used to study the role of ASMase in various cellular responses.  
A valuable tool to study the enzyme functions in vivo is the colony of ASMase 
knockout mice, which lack both the lysosomal and secretory forms of ASMase 
These mice also serve as source for a variety of cell types lacking ASMase 
activity and represent an animal model for the human disease since at age of 4 
months they develop the neurodegenerative phenotype seen in NPDA patients.  
Acute inhibition of ASMase has been achieved by the tricyclic amines such as 
desipramine and amitriptyline and is also frequently used in cell culture models. 
These amphiphilic drugs displace the enzyme from lysosomal membranes, 
making it vulnerable to proteolytic degradation [79].  
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The major goal of the studies presented in this chapter is to develop an 
experimental system in vivo and in vitro to study the regulation of TNF 
production in response to LPS, as well as to decipher the role of ASMase and 
ceramide in these regulatory mechanisms.  
  
 
B. Materials and Methods 
 
Materials  
 
LPS (E. coli, Serotype 026:B6), Desipramine hydrochloride, and Brewer 
thioglycollate broth were purchased from Sigma-Aldrich Co. (St. Luis, MO). The 
enhanced chemifluorescent kit was from GE Healthcare (Piscataway, NJ). 
Antibodies were from the following manufacturers: anti-phospho-ERK1/2, and 
anti-IRAK-1 were from Santa Cruz Biotechnology (Santa Cruz, CA); anti-TNF 
anti-cyclophilin A were from Cell signaling (Beverly, MA) anti--actin and alkaline 
phosphatase conjugated secondary antibodies were from Sigma-Aldrich Co. (St. 
Luis, MO). Trizol and Superscript IITM reverse transcriptase were from 
Invitrogen (Carlsbad, CA). Random hexamers were from Roche (Indianapolis, 
IN). Taq DNA polymerase was from New England Biolabs (Ipswich, MA). 
RNeasy Mini Kit and siRNAs (scrambled and ASMase-specific) were from 
Qiagen (Valencia, CA).  
 
Animals 
 
C57BL/6 mice were maintained in the AAALAC-approved animal facility of 
the University of Kentucky Medical Center and placed on a standard NIH-31 diet, 
with a 12-h light/dark cycle in microisolation. Mice were injected i.p. with LPS 
(5.8mg/kg b.w.) or an equivalent volume of 150mM NaCl. Blood was collected by 
cardiac puncture and serum was obtained in serum separator tubes.  
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Cell cultures and treatment 
 
RAW264.7 cells were maintained in DMEM supplemented with 100 
units/ml penicillin/streptomycin (Gibco Laboratories, Grand Island, NY) and 10% 
heat inactivated FBS. Cells were plated in 35mm dishes and used for 
experiments at a density of approximately 2x106 cells/dish.  
Two different ASMase-specific siRNAs (Quigen#SI00200753 and [80] ) 
were used for silencing of the endogenous ASMase expression. BLAST search 
confirmed that the sequences were specific for the smpd1 gene. Cells were 
plated in DMEM at density 0.7x106 cells/dish and transfections (160 pmol of 
siRNA per dish) were performed 16 hours later using LipofectamineTM according 
to the manufacturer’s instructions. Control plates were transfected with non-
silencing scrambled siRNA. Transfection efficiency was monitored after 
transfection with Alexa Fluor555-labeled scrambled siRNA.  
Treatments with LPS were done at 19 hours after plating. Where indicated, cells 
were pretreated for 2 hours with 25M Desipramine. 
Peritoneal macrophages were elicited with thioglycollate from 8 weeks old 
asm+/+ mice. Cells were plated in DMEM, and supplemented with 2% heat 
inactivated FBS on 6-well plates at a density of 2x106cells/well. Macrophages 
were allowed to adhere for 3 hours in a 37C humidified 5% CO2 incubator and 
non-adherent cells were removed by aspiration.  
Human fibroblasts from healthy individuals and patients with Niemann-
Pick Disease Type A were maintained in MEM supplemented with 15% FBS. 
Cells were plated in 60mm dishes and used for experiments at density of 
approximately 106 cells/dish. Cells and medium were used for Western blotting 
48 hours following transfection. 
 
 
SDS-PAGE and Western blotting of medium and cell lysates 
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Conditioned medium was collected from wells, each containing 2x106 
cells, cleared by centrifugation, and concentrated ten fold using Amicon Ultra 
tubes with a cutoff of 10kD. Ten microliters from the concentrated medium were 
subsequently used for Western blotting. Cells were lysed on ice for 30 min in a 
buffer containing 1mM EDTA, 1% Triton X-100, 1mM Na2VO4, 1mM NaF, and a 
protease inhibitor cocktail (1:200) in 10mM Tris-HCl, pH 7.4. Cell debris was 
removed by centrifugation at 16,000xg for 10min at 4C. Proteins were resolved 
by 10% SDS-PAGE, transferred to PVDF membranes and detected using the 
antibodies described above. Protein-antibody interactions were visualized using 
an ECF substrate and a Storm860 (Molecular Dynamics) Scanning Instrument, 
and analyzed using Image Quant 5.0 software.  
 
RNA isolation and cDNA synthesis 
 
Total RNA was isolated with Trizol Reagent (RAW 264.7 cells) or RNeasy 
Mini Kit (peritoneal macrophages) according to the manufacturer’s instructions. 
cDNA was generated from total RNA using Superscript II reverse transcriptase 
and random hexamers.  
 
Reverse transcription (RT)-PCR 
 
  cDNA from RAW264.7 cells was used as a template for RT-PCR analysis 
using primers specific for TNF (forward, 5’-tagccaggagggagaacaga-3’, reverse, 
5’- cacttggtggtttgctacga-3’) or -actin (forward, 5’-tatggagaagatttggcacc-3’, 
reverse, 5’-gtccagacgcaggatggcat-3’). PCR products were separated on 1.8% 
agarose gel in the presence of ethidium bromide. The specific bands for TNF 
(436bp) and -actin (300bp) were visualized under UV light. 
 
Quantitative real-time PCR 
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qRT-PCR was performed using TaqMan gene expression assays for 
mouse TNF (Mm00443258_m1) and GAPDH control (Applied Biosystems, 
Foster City, CA) according to the manufacturer’s instructions. Reactions were 
performed in triplicates in 96 well plates on an ABI Prism 7700 Sequence 
Detection System and analyzed with SDS 1.9.1 software (Applied Biosystems). 
Levels of TNF mRNA were normalized to GAPDH mRNA.  
 
ELISA 
 
The levels of TNF, IL-1, and IL-6 were determined by ELISA in 50l 
samples, according to the manufacturer’s protocol. The absorbance was 
measured at 450nm on a Vmax kinetic microplate reader with Softmax pro 
software (Molecular Devices). The sample values were calculated using a 
standard curve (0 - 1,500 pg/ml) and expressed per 106 cells or per ml serum. 
 
ASMase acitivity assay 
 
RAW264.7 cells were incubated for 2 hours in the absence or presence of 
25M desipramine. Cells were harvested and after centrifugation the pellet was 
re-suspended in PBS. Cells were homogenized by sonication and 20g of total 
protein was incubated in an assay mix (0.5M acetate buffer pH4.5, 3M NBD-
SM, 15mM NaF, 1mM -mercaptoethanol, protease inhibitors (1:200)) for 3h at 
37C. The reaction was stopped by addition of 0.5ml methanol. Cell debris was 
pelleted by centrifugation for 10 minutes at 16,000x g. The supernatants were 
analyzed by high performance liquid chromatography (HPLC) on a reverse-
phase column (Nova PAC, C18) using methanol: water: orthophosphoric acid 
(850: 150: 0.150 by volume) as a mobile phase at a rate 2 of ml/min. NBD-
ceramide formation was quantified after calibration using NBD-ceramide as an 
external standard. 
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Statistical analysis 
 
Significant changes in multiple comparisons of two independent variables 
(treatment and genotype) were determined by two-way ANOVA with Bonferoni 
post-test. To test for differences among two or more independent groups 
unpaired t-test and one-way ANOVA were also used. A P-value <0.05 was 
considered significant. Data are reported as mean  s.e.m (or  s.d). The star 
symbol indicates the significance of the main effect (treatment or genotype) and 
a pound symbol indicates the significance of the interaction effect in two-way 
ANOVA analysis.  
 
 
C. Results 
 
C.1. Studies in RAW264.7 cells 
 
Characterization of LPS signaling in macrophage cell line RAW264.7 
 
To test the response of RAW264.7 cells to LPS stimulation, the activation 
of cell signaling molecules in the TLR4 proximity was assessed. Upon stimulation 
of the receptor, the adaptor molecule IRAK-1 becomes phosphorylated and 
degraded and the rate of its degradation has been linked to the extent of MAP 
kinase activation [81]. Therefore, the degradation of IRAK-1 was first 
investigated. RAW264.7 cells were treated with 10ng/ml LPS for various times 
and the degradation of IRAK-1 was monitored by Western blotting. As 
anticipated, the levels of IRAK-1 gradually decreased for up to 90 min following 
stimulation (Fig. 2.2 A). Next, the activation of downstream targets JNK and ERK 
was also tested by Western blotting using antibodies against the phosphorylated 
forms of these MAP kinases. In untreated control cells pJNK and pERK were 
almost undetectable, but transient phosphorylation of both kinases was 
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demonstrated in response to LPS, with maximum response at 30-40 min after 
stimulation followed by a decrease (Fig. 2.2 B, C). Dose dependent 
phosphorylation of JNK and ERK to increasing concentrations of LPS revealed 
that at 30 min, 5-10ng/ml of LPS was sufficient to induce maximum response 
(Fig. 2.3 A, B). These data indicate that RAW 264.7 cells respond potently to 
stimulation with LPS. 
 
Production and release of TNF by LPS stimulated RAW264.7 cells 
 
To understand the dynamics of TNF production and secretion by 
RAW264.7, the levels of TNF mRNA were measured by RT-PCR, while the 
levels of TNF in cell lysates and conditioned medium were measured by 
Western blotting. LPS-induced production of TNF mRNA was detectable as 
early as 1 hour after stimulation and was maintained for up to 6 hours (Fig. 2.4 
A). At the protein level, the TNF detected in the cell lysates corresponded to the 
26kD precursor form, while in the medium a band with a molecular weight of 
17kD was found and represented the mature sTNF, which was additionally 
confirmed with the positive control recombinant TNF (Fig. 2.4 B). The dynamics 
of TNF production and cleavage was further followed. In RAW264.7 cells 
proTNF was detected as early as 2 hours and remained elevated for at least 10 
hours, although some decrease was observed after 6h (Fig. 2.4 C). The 
appearance of sTNF in the medium followed closely the levels of proTNF in 
the cells, showing a slight delay in secretion. sTNF was first detectable at 4 
hours and continued to accumulate for at least 6 more hours (Fig. 2.4 D). In 
agreement with previous studies, a 17kDa unmodified form of sTNF was 
predominant in the medium, although bands with a higher molecular weight were 
also detected (Fig. 2.4 D). It has been suggested that the majority of the proteins 
in the “ladder” are N-glycosylated forms of the 17kD sTNF [77].  
 
C.2. Studies in primary peritoneal macrophages 
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Induction of TNF mRNA synthesis and sTNF secretion in primary 
peritoneal macrophages after stimulation with LPS 
 
 Primary peritoneal macrophages were also tested as a more 
physiologically relevant cell culture model to study TNF secretion in response to 
LPS. First, peritoneal macrophages were stimulated with 10ng/ml LPS and the 
levels of TNF mRNA were measured by quantitative real-time PCR. Similarly to 
RAW264.7, in primary macrophages LPS induced robust synthesis of TNF 
mRNA, which at its peak levels (4 hours) was more than a 100 fold higher 
compared to the vehicle treated control (Fig. 2.5 A). This induction, however was 
transient and at 6 hours post LPS a decrease in TNF mRNA abundance was 
apparent.    
 The secretion of TNF by activated macrophages was monitored by 
Western blotting. As expected, sTNF accumulated in the medium with a similar 
kinetic as observed in RAW264.7 cells: it was detectable at 4 hours and 
increased at the later time points (Fig. 2.5 C). Furthermore, there was neither 
difference in the molecular size of the major 17kDa unmodified form nor in the 
glycosylation pattern between both cell types. However proTNF in cell lysates 
from peritoneal macrophages was almost undetectable even though the amount 
of total protein which was loaded was the same as in RAW cells (Fig. 2.5 B). 
These results may indicate that despite a strong activation of LPS signaling and 
TNF synthesis in both cell types, there might be a significant difference in post-
translational processing of proTNF. 
 
C.3. Studies in mice 
 
Dynamics of cytokine production in response to LPS in vivo 
 
To develop a model to study TNF production in vivo, mice were injected 
with saline or sub-lethal dose of LPS (5.8mg/kg) and the serum levels of TNF, 
IL-1, and IL-6 were measured by ELISA. The administration of LPS led to mild 
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and temporary inflammatory reaction in the host. A slight elevation in body 
temperature and lack of tonus were observed within a couple of hours. In all 
animals, these symptoms disappeared after approximately 6 hours. Control 
animals had undetectable levels of TNF and IL-1, but IL-6 ranged from 2 to 
4ng/ml (Fig. 2.6 C, 0 time LPS). However, i.p. administration of LPS quickly 
induced a sharp but transient increase in the circulating levels of all three 
cytokines. Among them, the increase in TNF secretion was the most rapid and 
dramatic, reaching 2.5ng/ml (more than 2000 fold increase over control animals) 
1 hour after LPS injection (Fig. 2.6 A). The maximum levels of IL-1 and IL-6 
were detected at 2h post stimulation (Fig. 2.6 B, C). These data are in agreement 
with previously published results and underlines the significance of TNF as one 
of the earliest and most potent pro-inflammatory cytokines secreted during 
sepsis.  
 
C.4. ASMase-deficient cells and animals as a model to study the role of 
ASMase in the LPS-induced TNF synthesis 
 
 To study the role of ASMase and ASMase-derived ceramide in the 
regulation of TNF production different in vivo and in vitro models were 
developed. 
 
C.4.1. Inhibition of ASMase in RAW264.7 cells 
 
 To generate ASMase deficiency in RAW264.7 cells, a pharmacological 
inhibition of ASMase activity was first used. Desipramine is a cationic amphiphilic 
drug, which accumulates in the acidic compartments of living cells, since it is 
trapped as membrane-inpermeable form subsequent to its protonation in the 
acidic environment. This tricyclic amine decreases the binding of ASMase to its 
membrane-bound lipid substrate, which exposes the enzyme to lysosomal 
proteases and make it susceptible to proteolytic degradation [79]. Desipramine is 
widely used to inhibit ASMase activity, although some effects on acid ceramidase 
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have been also reported [80]. Treatment with 25M desipramine was sufficient to 
inhibit more than 90% of ASMase activity in RAW264.7 cells when it was applied 
for 2 hours (Fig. 2.7 A). Importantly, the activity of Neutral sphingomyelinase 
(NSMase) in the same cells was not influenced by desipramine (Fig. 2.7 B). 
NSMase is the other signaling enzyme, which upon activation hydrolyzes 
sphingomyelin to ceramide; therefore, this result suggests that desipramine 
inhibits only the generation of ceramide by ASMase but not NSMase. 
 siRNA-mediated silencing was also tested as an alternative approach to 
suppress ASMase activity in RAW264.7 cells. Using fluorescently labeled siRNA 
(non-silencing siRNA-AlexaFluor555) the transfection conditions were first 
optimized to ensure maximal transfection efficiency. More than 70% of the cells 
contained siRNA based on the immunofluorescence (Fig. 2.8 A,B). Then, two 
different ASMase-specific siRNAs were used to knockdown ASMase. However, 
24 and 48 hours after transfection the activity of ASMase was not different 
between the cells transfected with either of the silencing siRNAs and scrambled 
siRNA. A maximum of 10% inhibition was achieved at 72 hours after trasfection 
but it was still not significant compared to control cells (Fig. 2.8 C). Therefore, 
inhibition by desipramine but not silencing of ASMase by siRNA was used in 
further studies to inhibit ASMase in RAW264 cells. 
 
C.4.2. Testing of ASMase-deficient fibroblasts, acquired from 
Niemann-Pick Disease patients and control healthy individuals, as a model 
to study the role of ASMase in TNF production in response to LPS 
 
Niemann-Pick disease (NPD) belongs to lysosomal storage diseases and it is 
characterized by a lack of ASMase activity. Mutations in the ASMase gene cause 
an abnormal accumulation of sphingomyelin, and in patients with the more 
severe form of the disease (type A) this affects the function of visceral organs 
and brain, and leads to lethality at an early age. Fibroblasts from patients with 
NPDA are often used to study the role of ASMase in various cellular responses.  
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Therefore, we tested fibroblasts from individuals with NPDA and healthy 
controls with intact ASMase activity as a model for deciphering the role of 
ASMase in TNF production. After confirming the absence of ASMase activity in 
firbroblasts from NPDA patients (Fig. 2.9 A), control fibroblasts were treated with 
increasing concentrations of LPS and the levels of proTNF in cells and sTNF 
in medium were monitored by Western blotting. However, TNF was not 
detectable either in the cells or in the medium even after treatment with 1g/ml 
LPS, which is a concentration 100 fold higher compared to that used for 
treatment of macrophages (Fig. 2.9 B, C). Raw264.7 cells were used as a 
positive control in these experiments. Thus, these results demonstrated that 
fibroblasts were not an appropriate system to study TNF secretion. 
 
C.4.3. ASMase-deficient mice and macrophages as a model to study 
the role of ASMase in LPS-induced TNF production  
 
 Asm-/- mice are the animal model of the human genetic disease NPDA. 
Therefore, asm-/- and litter-matched asm+/+ (Fig. 2.10) mice, as well as peritoneal 
macrophages isolated from these mice, are a physiologically relevant model to 
understand the role of ASMase in TNF production in response to LPS.  
 
D. Discussion 
 
The data presented in this chapter demonstrated that macrophages 
responded rapidly and strongly to LPS stimulation since the maximum activation 
of MAP kinases, ERK and JNK, was achieved 30-40 min following stimulation 
and as little as 1ng/ml of LPS was able to induce their phosphorylation. As 
discussed earlier the activation of MAPK has been strongly correlated with TNF 
production. Consistent with these findings, LPS induced potent secretion of 
TNF in both isolated peritoneal macrophages and the macrophage cell line, 
RAW264.7. Importantly, the time course for detection of TNF in the medium as 
well as the molecular weight of TNF were essentially the same for both cell 
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types. Although the 17kD unmodified form was the most abundant, additional 
bands with higher molecular weight were also detectable when substantial 
amount of medium was used for Western blotting. This pattern of “protein ladder” 
is consistent with previous studies demonstrating that the higher molecular bands 
represent TNF glycosylated at different positions [77]. The physiological 
significance of this modification is currently unknown. However it has been 
shown that it does not influence the activity of sTNF [78]. 
RAW 264.7 cells and primary peritoneal macrophages appeared to be 
similar in terms of sTNF secreted in the medium, however there was a striking 
difference in the levels of proTNF detected in cell lysates. Despite equal 
amounts of total protein used for Western blotting, proTNF was almost 
undetectable in primary cells but abundant in RAW264.7 cells. These results 
indicate that there might be cell specific differences in the post-translational 
processing of proTNF by RAW 264.7 cells and peritoneal macrophages.  
 Differences were also apparent between LPS-induced TNF secretion in 
vivo and in vitro, since the stimulation of TNF was much more rapid in vivo than 
in vitro - systemic TNF peaked at 1 hour, while the earliest time point at which 
TNF was detected in the medium was 4 hours.  Additionally, the increase in 
TNF levels was much more transient in vivo than in vitro; TNF in the serum 
reached almost basal levels 6 hours after LPS administration, while in the 
medium it was readily detectable for more than 10 hours. Although the exact 
mechanisms for these differences are not precisely defined, there are several 
plausible explanations: Since the levels of TNF mRNA started to decline after 4 
hours, the accumulation of TNF in the medium is most likely due to the lack of 
effective clearance mechanisms in vitro. In the circulation TNF is rapidly cleared 
by the kidneys and liver, with estimated half-life of 6 to 20 min [82]. The delayed 
secretion of TNF in vitro also can be due to the absence of factors, such as 
LBP, which have co-stimulatory effect in vivo, and facilitate the binding of LPS to 
the receptor and initiation of signal transduction. This possibility is further 
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supported by findings reported by Wollenberg et al. [83], that not only sTNF but 
also TNF mRNA reaches its peak levels much faster in vivo than in vitro.  
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Figure 2.1. TNF synthesis and secretion in response to LPS stimulation. 
The binding of LPS to the TLR4 signaling receptor induces phosphorylation and 
degradation of the adaptor molecule IRAK-1, which is essential for activation of 
downstream targets including MAP kinases. Phosphorylation of JNK, ERK, and 
p38, as well as degradation of I-B, ultimately lead to nuclear translocation of 
transcription factors such as NF-B, Elk-1, Egr-1, ATF-3, which are implicated in 
the initiation of TNF gene transcription. LPS stimulation increases the stability of 
TNF mRNA, which is translated into 26kD TNF precursor (proTNF). proTNF 
is transferred to the plasma membrane, where it is cleaved by TACE to produce 
the 17kD soluble biologically active TNF (sTNF). 
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Figure 2.2. Time course of IRAK-1 degradation and phosphorylation of ERK 
and JNK in RAW264.7 cells stimulated with LPS.  RAW264.7 cells were 
treated with LPS (10ng/ml) for the indicated time. The rate of IRAK-1 degradation 
(A, B) and phosphorylation of JNK (C, D) and ERK (E, F) was detected by 
Western blotting using specific antibodies. Cyclophilin A was used to ensure 
equal protein loading. Representative image is shown and the quantification of 
the band intensity for IRAK-1, pJNK, and pERK is presented normalized to the 
levels of cyclophilin A in the same sample (B, C, D) 
 
30 
 
 
 
Figure 2.3. Dose dependent phosphorylation of ERK and JNK after LPS 
treatment. RAW264.7 cells were treated for 30min with increasing 
concentrations of LPS. Phosphorylation of JNK (A, B) and ERK (C, D) was 
determined by Western blotting using antibodies specific for the phosphorylated 
forms of JNK and ERK. Cyclophilin A was used to control for uniform loading. 
Representative image is shown and the quantification of the band intensity for 
pJNK, and pERK is presented after normalization to the levels of cyclophilin A in 
the same sample (B, D).  
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RAW264.7 cells 
 
 
 
 
 
Figure 2.4. TNF mRNA levels and post-translational processing of TNF 
precursor in RAW264.7 cells. RAW264.7 cells were treated with LPS (10ng/ml) 
for the indicated times. A. TNF mRNA levels. Total RNA was isolated by Trizol 
reagent and the levels of TNF mRNA were determined by RT-PCR. The 
expression level of -actin mRNA was used to control for uniform loading (A). B-
D. TNF processing. The kinetics of 26kD proTNF processing to 17kD sTNF 
was determined by Western blotting. Recombinant human TNF was used as a 
positive control for sTNF (B). Time course of proTNF production in cell lysates 
(C) and its cleavage to sTNF measured in the medium (D).  
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Primary peritoneal macrophages 
 
 
 
 
 
Figure 2.5. TNF mRNA levels and post-translational processing of TNF in 
primary peritoneal macrophages. Peritoneal macrophages were isolated from 
C57BL/6 mice and treated with LPS (10ng/ml) for the indicated times. A. TNF 
mRNA expression. The levels of TNF mRNA in each sample were measured 
in triplicates by quantitative real-time PCR and normalized to GAPDH levels in 
the same sample. The results from two independent experiments are shown and 
expressed as percent of the maximum response (A). B and C. TNF 
processing. The levels of proTNF in cell lysates (B) and sTNF in the medium 
(C) were determined by Western Blotting. -actin levels were used to control for 
uniform loading.  
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Figure 2.6. Cytokine levels in LPS-injected C57BL/6 mice.  
C57BL/6 mice were injected i.p. with LPS (5.8mg/kg body weight) or saline. 
Serum was collected at the indicated times and the levels of TNF (A), IL-1 (B), 
and IL-6 (C) were measured by ELISA. Only the data for LPS-injected animals 
are shown.  The levels of the cytokines in saline-injected animals were below the 
detection levels for TNF and IL-1 and were around 2ng/ml for IL-6 (C). The 
combined data from three independent experiments are shown as group average 
 s.e.m. The significance of the LPS treatment effect (**, P<0.01, *, P<0.05) is 
based on one-way ANOVA.  
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Figure 2.7. Effect of desipramine on ASMase and NSMase activity in 
RAW264. 7 cells. RAW264.7 cells were treated with desipramine (25M) for 2 
hours. ASMase (A) and NSMase (B) activities were measured in cell lysates by 
using NBD-sphingomyelin as a substrate and HPLC method. Statistical 
significance of desipramine effect is shown (***<0.001) based on unpaired 
student t-test. 
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Figure 2.8. ASMase silencing by siRNA in RAW264.7 cells. RAW264.7 cells 
were transfected with either scrambled or ASMase specific siRNA. Transfection 
efficiency at 6 hours is shown after using scrambled siRNA labeled with Alexa 
Fluor 555 and fluorescent microscopy (A). Transmitted light images of RAW264.7 
cells (B). ASMase activity was measured in cell lysates from RAW264.7 cells 
transfected for 24, 48, or 72 hours with control or ASMase specific siRNA. Two 
different ASMase specific siRNAs were used designated as ASMase siRNA 1 
and ASMase siRNA 2 (C).  
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Figure 2.9. Characterization of LPS response in human fibroblasts. A. 
ASMase activity. ASMase activity in fibroblasts from healthy individuals or 
patients with type A Niemann-Pick Disease measured by the HPLC method (A).  
B and C. TNF levels. Human skin fibroblasts from healthy individuals were 
treated for 4 hours with increasing concentrations of LPS and the levels of 
proTNF in cell lysates (B) and sTNF in medium were determined by Western 
blotting. Cell lysate and medium from LPS stimulated RAW264.7 cells were used 
as a positive control.  
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Figure 2.10. ASMase-deficient mice - an in vivo model to study the role of 
ASMase in TNF secretion.  The offspring of heterozygous (asm+/-) breeding 
pairs were genotyped after weaning by using PCR of tail DNA. Around 25% of 
the mice were asm-/- and had single PCR product of 550bp. Litter-matched asm+/+ 
controls were also around 25% of the offspring and had single PCR product of 
300bp. In the heterozygous mice two bands corresponding to 550bp and 300bp 
were detectable.  
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CHAPTER THREE 
 
Role of ASMase and ceramide in the transcriptional regulation of TNF 
synthesis in response to LPS 
 
A. Introduction 
 
LPS is one of the most potent agonists that activates mononuclear cells to 
produce TNF. The recognition of LPS by macrophages is mediated by LBP, 
which binds to the lipid A moiety [84] and greatly increases host sensitivity to 
LPS [85]. LBP-LPS forms a ternary complex with CD14, which enables LPS to be 
transferred to the signal transducing receptor complex. CD14 exists in two forms: 
a soluble CD14, which is found in the plasma; and membrane-bound CD14, 
which is attached to the surface of myeloid cells via a 
glycosylphosphatidylinositol anchor. The LPS-specific receptor complex is 
composed of Toll-like receptor-4 (TLR4) and MD-2. MD-2 is secreted 
glycoprotein and acts as an extracellular adaptor protein in the activation of 
TLR4. MD-2 is important for ligand recognition by TLR4 and is essential for LPS 
signaling to occur. Mice lacking MD-2 are unresponsive to LPS [86]. TLR4 is the 
first-discovered mammalian homologue of Drosophila Toll. TLR4 works 
downstream of CD14 and is responsible for delivering an LPS signal. 
Homodimerization of TLR4 recruits to the receptor complex adaptor proteins Mal 
and MyD88, which, analogously to the IL-1 signaling, associate with IRAK-1 
causing its phosphorylation. Phosphorylation of IRAK-1 is followed by its 
ubiquitination and proteosome-mediated degradation, which determines the 
magnitude of TLR response. For example, inhibition of IRAK-1 degradation in 
macrophages by inhibitors of ubiquitin ligases has been found to potentiate the 
inflammatory response, as judged by a more potent induction of JNK [87]. In turn, 
decreased stability of IRAK-1 underlies the decreased response to a second 
dose of LPS and is the cause of endotoxin tolerance [88].  
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Hyperphosphorylation of IRAK-1 is also important for dissociation from the 
receptor complex and association of IRAK with TRAF6, which is critical for the 
activation of MAPK kinase TAK-1. TAK-1 acts as a common activator of NF-B 
as well as of p38 and JNK. The activation of MEK/ERK1/2 pathway in response 
to LPS appears to be Raf-1 dependent.  
Most of the above mentioned signaling molecules have been shown to be 
essential for TNF production and are implicated in various mechanisms of its 
regulation. For example, stimulation of LBP production by LPS [89] has been 
linked to an increase in TNF mRNA synthesis and stability [90]. The 
requirement of CD14 for TNF synthesis was reinforced by the inhibition of TNF 
production in the presence of blocking antibodies to CD14 [91]. Additionally, a 
number of studies unequivocally demonstrated the importance of MAPK and NF-
B for LPS induced TNF production. For example, dominant-negative forms of 
both Rac and c-Raf inhibited LPS induction of TNF promoter in RAW264.7 cells 
[62]. It has also been found that treatment of cells with ERK inhibitor, PD-098059, 
reduced TNF mRNA expression in a dose dependent manner; and TNF 
secretion was completely abolished in the presence of Ro 09-2210, a MEK 
inhibitor which blocks the activation of not only ERK1/2, but also JNK and p38 
[73]. Additional studies further supported the role of p38 activation for TNF 
production [74], and also suggested that JNK and p38 might be involved in the 
translational regulation of TNF [75, 92, 93].  
The enhancement of transcription initiation, release of the transcript 
elongation block, and transcript stabilization contribute to the accumulation of 
TNF mRNA in stimulated macrophages [94, 95]. Transcription factors such as 
c-Jun, ATF-2, Egr-1, and Elk-1 [96], which are downstream targets of MAPK 
have been shown to be essential for the initiation of transcription and RNA 
synthesis. Many of the above mentioned factors bind to the proximal promoter 
region, which plays an important functional role in the transcriptional regulation of 
mouse TNF [97]. Chromatin immunoprecipitation revealed that ATF-2, c-Jun, 
Elk-1, and Ets-1 bind to this region in J774 cells [98]. 5’ distal NF-B sites are 
also important for maximum functional activity of mouse TNF gene [68, 97, 99]. 
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Finally, a mutation in the Egr-1 site in the TNF promoter significantly reduced 
the level of LPS induction [67].  Once transcribed, TNF mRNA is stabilized after 
LPS stimulation. Cis-acting elements in the TNF 3’-untranslated region are 
sufficient for LPS-induced activation of TNF translation [76, 100]. All three MAP 
kinases, ERK, JNK and p38 have been implicated in the regulation of TNF 
mRNA stability [75, 101, 102]. 
The generation of ceramide in response to various stimuli has been linked 
to both up-regulation and down-regulation of NF-B and MAPK activity in 
different cell types. In IL-1 stimulated primary hepatocytes, ceramide produced 
by NSMase led to an increase in JNK phosphorylation [81]. Activation of JNK by 
ASMase-derived ceramide has also been reported after stimulation with UV light 
[103], and after infection with Pseudomonas aeruginosa [104]. However, 
ceramide generated after infection with protozoan parasite Leishmania donovani 
inhibited ERK phosphorylation [105] and suppressed AP-1 and NF-B activation 
[106]. Cell permeable C2-ceramide was shown to stimulate ERK activation, which 
appeared to be important for smooth muscle contraction [107]. However, in RBL-
2H3 cells C2-ceramide suppressed phosphorylation of ERK and p38 [108]. 
Finally, ceramide stimulated p38 phosphorylation in HL-60 cells [109] but it was 
linked to p38 dephosphorylation in PMA stimulated human breast cancer cells 
[110]. 
Modulation of MAPK and NF-B activity, which are essential for TNF 
transcriptional and translational regulation by ceramide, suggests that it might 
play a role in TNF production. The effects of ceramide, however, appear to 
depend on the stimulus, cell type, and pathway for its generation. Therefore, this 
chapter investigated the role of ASMase-derived ceramide in LPS-induced 
transcriptional regulation of TNF production. 
 
 
B. Materials and Methods 
 
Materials 
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Bacterial sphingomyelinase (S. Aureus) was purchased from Sigma-
Aldrich Co. (St. Luis, MO). C2-ceramide was from Avanti Polar Lipids (Alabaster, 
AL). 
 
Animals 
 
A colony of ASMase knockout (asm-/-) mice maintained in C57BL/6 
background were propagated using heterozygous breeding pairs and genotyped 
by PCR of tail DNA. The mice received food and water ad libitum and were 
housed in AAALAC-approved animal facility of the University of Kentucky 
Medical Center. Litter-matched wild-type (asm+/+) and asm-/- mice were used for 
experiments.  
 
SDS-PAGE and Western blotting 
 
Please refer to Chapter Two, Section B. 
 
RNA isolation, Reverse transcription (RT)-PCR, and Quantitative real-time 
PCR analysis 
 
Please refer to Chapter Two, Section B. 
 
ELISA 
 
The levels of TNF in the medium from asm+/+ and asm-/- miacrophages 
were determined by ELISA as described in Chapter one, Section B. 
 
Statistical analysis 
 
Please refer to Chapter Two, Section B. 
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C. Results 
 
Genotype-specific differences in the level of TNF secreted by 
macrophages stimulated with LPS 
 
To test whether ASMase deficiency affected the production of TNF, 
peritoneal macrophages were isolated from asm+/+ and asm-/- animals and 
stimulated with LPS. The release of TNF in the medium was monitored by 
ELISA. As anticipated, treatment with LPS induced TNF secretion, which 
reached maximum at 4 hours after stimulation. However, TNF levels were up to 
2 fold higher in asm-/- macrophages as compared to asm+/+ cells (Fig. 3.1 A), 
although the difference tended to decrease at later time points (6 hours). 
Furthermore, the effect of ASMase seems to be specific for TNF secretion, 
since the levels of IL-1 were not significantly different between asm+/+ and asm-/- 
macrophages (data not shown). ASMase deficient macrophages lack one of the 
major enzymes responsible for the generation of ceramide, therefore to 
demonstrate a direct link between ceramide and sTNF levels, asm-/- were 
treated with cell permeable C2-ceramide and TNF levels were measured in the 
medium. The addition of short-chain ceramide to asm-/- macrophages inhibited 
sTNF secretion in a dose dependent manner (Fig. 3.1 B).  Together, these 
results indicate that ASMase and ceramide may regulate specific step(s) in TNF 
production. 
 
Effects of ASMase on TNF levels are not mediated by PGE2 or IL-6 
 
The secretion of TNF by LPS-activated macrophages can be modulated 
by a variety of pro- and anti-inflammatory mediators induced by LPS or TNF 
itself. Therefore, it is important to understand whether ASMase directly affects 
LPS-induced TNF production, or if it acts through secondary mechanisms.  
Since PGE2 is one of the well-known negative regulators of TNF secretion, its 
levels were measured in medium from asm+/+ and asm-/- macrophages. PGE2 
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secretion was induced after LPS stimulation and gradually increased for at least 
up to 8 hours. However asm-/- and control cells released similar levels of PGE2 at 
all time points tested, suggesting that the differences in TNF secretion are not 
attributable to a defect in PGE2 production (Fig. 3.2 A). Similarly, the 
simultaneous treatment with IL-6, which can also suppress TNF synthesis, had 
no effect on the genotype-related differences (Fig. 3.2 B).  
 
ASMase deficiency has no effect on MAP kinase activation and TNF 
mRNA production in peritoneal macrophages 
 
To determine whether the observed differences in TNF secretion are 
related to differences in the LPS signaling pathway at the plasma membrane, the 
activation pattern of proteins proximal to the LPS receptor was first examined. 
However, the IRAK-1 degradation rate was not different between genotypes (Fig. 
3.3 A, B). Similarly, the pattern of ERK phosphorylation was not affected by the 
lack of ASMase activity (Fig. 3.3 C, D). Finally, the magnitude and time course of 
LPS-induced TNF mRNA production was the same in both genotypes (Fig. 3.3 
E). These results are in agreement and extend previous studies that examined 
the activation of MAP kinase pathway in macrophages from asm-/- and asm+/+ 
mice, and found no differences in the ability of TNF and LPS to induce 
activation of ERK, JNK, p38 and NF-B [111]. 
 
Inhibition of ASMase by desipramine affects neither LPS-induced 
phosphorylation of ERK and JNK nor TNF mRNA synthesis 
 
 The effect of ASMase on transcriptional regulation of TNF was also 
tested in RAW264.7 cells, where acute inhibition of ASMase was achieved after 
treatment with desipramine. Although desipramine suppressed ASMase activity 
by more than 90% (See chapter two, Fig. 2.5 A), which was consistent with the 
results from primary macrophages, the extent of MAP kinase phosphoryaltion 
and induction of TNF mRNA synthesis were similar among treatments and were 
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not influenced by ASMase deficiency  (Fig. 3.4 A, B, C, D). Furthermore, the 
treatment of RAW264.7 cells with either C2-ceramide or bacterial 
sphingomyelinase, both of which increased ceramide levels, did not have any 
effect on TNF mRNA levels (Fig. 3.4 E). Altogether these results suggest that 
ASMase and ceramide do not affect transcriptional regulation of TNF 
production. 
 
D. Discussion 
 
 The activation of ASMase by LPS followed by the generation of ceramide 
have been previously reported and suggested to be important for the initiation of 
signal transduction and regulation of the activity of signaling molecules such as 
MAPK.  The results presented in this chapter demonstrated that ASMase is 
involved in the regulation of TNF production following LPS stimulation, and the 
lack of ASMase activity was linked to increased levels of sTNF, suggesting that 
it plays a role of negative regulator of TNF production. Additional treatments 
confirmed such a conclusion, demonstrating that exogenous ceramide is 
sufficient to decrease sTNF in the medium. ASMase and ceramide appear to 
influence directly LPS-induced TNF production, rather than working via 
secondary mechanisms. However, the activation of ERK and JNK as well as the 
levels of TNF mRNA were not influenced by ASMase deficiency in neither 
primary macrophages nor RAW 264.7 cells, indicating that ASMase and 
ceramide most likely affect step(s) of TNF production downstream of TNF 
mRNA synthesis.  
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Figure 3.1. Effect of ASMase and ceramide on TNF production in primary 
macrophages. TNF levels measured by ELISA in medium of peritoneal 
macrophages from asm+/+ (filled symbols) or asm-/- (open symbols). Cells treated 
with LPS (100ng/ml, circles) or PBS (triangles) for the indicated times. 
Representative results of three independent experiments are shown (A).   Cells 
treated with LPS (10 ng/ml) for 4 hours in the presence of the indicated 
concentrations of C2-ceramide or vehicle control (0.1% ethanol). Results 
combined from two independent experiments are shown (B). Data are presented 
as mean ± s.e.m. Statistical significance of the main effect (***, P<0.001) and the 
interaction effect (###, P<0.001; #, P<0.05) are shown based on two-way 
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ANOVA. The statistical significance of ceramide effects was calculated by one-
way ANOVA (*, P<0.05). 
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Figure 3.2. Role of ASMase deficiency on PGE2 production and IL-6 effects 
on TNF secretion. Peritoneal macrophages from asm+/+ (filled bars) or asm-/- 
(open bars) were treated with LPS (10ng/ml) for the indicated time. The levels of 
PGE2 in cell-free conditioned medium were determined by ELISA and the results 
were normalized to the cyclophilin A measured in the cells (A). Peritoneal 
macrophages from asm+/+ or asm-/- were treated for 4 hours with LPS (10ng/ml) 
in the absence or presence of IL-6 (20ng/ml). The levels of TNF (ng/ml) in the 
medium were measured by ELISA. 
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Figure 3.3. Stimulation of IRAK-1, ERK, and TNF mRNA in asm+/+ and asm-
/- macrophages. Peritoneal macrophages from asm+/+ (filled bars) and asm-/- 
(open bars) mice were treated with LPS (10ng/ml) for the indicated times. A-D. 
Activation of IRAK-1 (A, C) and ERK1/2 (B, D). Analyses were done using 
Western blotting and antibodies against IRAK-1 and phosphorylated ERK. Data 
are representative of three independent experiments.  -Actin levels were used 
to control for uniform loading. (E) Stimulation of TNF mRNA. mRNA levels 
were determined by real-time PCR. GAPDH mRNA level was used for 
normalization.  Data are presented as mean ± s.e.m. of three independent 
experiments. Statistical significance of the treatment effect is shown (***, 
P<0.001) based on two-way ANOVA. 
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Figure 3.4. Phosphorylation of ERK and JNK, and production of TNF 
mRNA in LPS stimulated ASMase deficient and control RAW264.7 cells. A-
D. Effect of ASMase deficiency on the LPS-induced activation of ERK and 
JNK. RAW264.7 pre-treated with desipramine (25M) to inhibit ASMase activity 
and control cells were stimulated with LPS (10ng/ml) for 60 min. Phosphorylation 
pattern of ERK (A) and JNK (C) after LPS stimulation was determined by 
Western blotting using antibodies specific for the phosphorylated forms of these 
MAP kinases. Quantification of pERK and pJNK band intensity is shown after 
normalization to the cyclophilin A (B,D), used as a control for equal protein 
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loading.   E. Effect of ASMase deficiency and exogenous ceramide on TNF 
mRNA production in RAW264.7 cells. RAW264.7 cells were treated for 2 hours 
with LPS (10ng/ml) alone or in the presence of either desipramine (25M), C2-
ceramide (60M), or bacterial sphingomyelinase (0.1units/ml). The steady-state 
levels of TNF mRNA were determined by RT-PCR. 
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CHAPTER FOUR 
 
Role of ASMase and ceramide in the post-translational regulation of TNF 
synthesis in response to LPS 
 
A. Introduction 
 
The concept of post-translational regulation of TNF secretion in response 
to LPS has been proposed more than 20 years ago [112]. However, the 
mechanisms which regulate the rates of trafficking, processing, and release of 
TNF (Fig. 4.1) remain mostly unknown.  
In mice, TNF mRNA is translated into a 26kD precursor most of which is 
associated with the Golgi complex [113]. Part of the newly synthesized protein is 
immediately N-glycosylated [77]. proTNF residing in Golgi is selected as a 
cargo for the golgin p230-positive vesicles [114]  which fuse with rab11 recycling 
endosomes en route to the plasma membrane [115].  The precursor is not 
delivered randomly to the cell surface but it is highly concentrated in the 
phagocytic cups [116] where it is integrated as a type II membrane protein. The 
proteolytic cleavage of proTNF to the biologically active 17kD sTNF is 
inhibited by cholesterol depletion and hydroxymate inhibitors, suggesting that it 
takes place in cholesterol-rich membrane domains and the enzyme responsible 
for proTNF shedding is a metalloprotease [116-118]. Indeed, it was confirmed 
that at the membrane, proTNF ectodomain is cleaved by TACE, which is a 
member of the ADAM (A Disintegrin And Metalloproteinase) family of proteases 
[119]. In addition to TNF, TACE also processes the two TNF receptors (p55 
and p75), transforming growth factor alpha (TGF), L-selectin, and other 
secretory proteins.  
Recent studies on TNF processing revealed that TACE activity might be 
a rate-limiting step in TNF secretion [120]. For example, it was reported that a 
substantial portion of proTNF that was not cleaved by TACE was rapidly 
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internalized and either degraded in the lysosomes or recycled back to the plasma 
membrane [121, 122].   
TACE mRNA is expressed in most tissues and gives rise to an inactive 
zymogen. Removal of the autoinhibitory prodomain occurs in a late Golgi 
compartment, most likely by the action of furin or a related protease [123].  Only 
processed TACE appears on the cell surface [124]. The stimulation of cells with 
various agents can increase the rate of shedding. However, the mechanisms 
underlying the regulation of TACE activity remain poorly understood. A role of the 
cytoplasmic domain was suggested in response to intracellular signaling events 
such as MAP kinase activation [125]. In favor of this is the finding that the 
cytoplasmic domain is phosphorylated in response to shedding activators [126]. 
Nevertheless, TACE constructs lacking the entire cytoplasmic domain are fully 
functional in shedding [127], indicating that other mechanisms must be also 
involved. Another important question is what determines substrate selectivity of 
the enzyme. Since the sequences cleaved in various substrates are highly 
variable it was proposed that the distance between the membrane domain and 
the cleavage site is important. However, interactions distal to the cleavage site 
also appear to be required [127]. Finally, there is evidence to suggest that spatial 
segregation or proximity of enzyme and substrate within the plasma membrane 
may control some shedding activity.  
At the plasma membrane, TACE activity appears to depend upon 
compartmentalization of the protein in the ordered lipid domains. It is 
controversial, however, whether localization in the ordered lipid rafts is linked to 
stimulation or to inhibition of activity. It is also not known whether these observed 
changes reflect differences in the co-localization of TACE and its substrates, or a 
conformational change and catalytic activation of the enzyme.  
Lipid rafts are loosely defined as domains on the plasma membrane that 
are enriched in sphingomyelin and cholesterol. They constitute a unique liquid 
ordered environment that includes or excludes specific subsets of proteins and 
lipids. Sphingomyelin and cholesterol have a unique relationship in mammalian 
cells that involves physical and metabolic interactions. First and foremost, the 
presence of cis-, but not trans- double bond in the sphingoid moiety of 
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sphingomyelin makes the molecule “flat”. This allows for close hydrophobic 
interaction between sphingomyelin and cholesterol, evident by their ability to 
aggregate in domains that exclude other lipids. Furthermore, the importance of a 
hydrogen bond formed between the amide nitrogen of sphingomyelin and the 
oxygen atom in the cholesterol hydroxyl group has also been suggested as a 
structural basis for sphingomyelin:cholesterol complex formation [128, 129].  
Translocation of ASMase to the plasma membrane leads to hydrolysis of 
sphingomyelin and generation of ceramide, followed by exclusion of cholesterol 
from the rafts and formation of large ceramide-enriched macrodomain platforms 
[130].  
Interestingly, the two lipids, sphingomyelin and cholesterol, affect each 
other’s metabolism. Lowering of the content of sphingomyelin at the plasma 
membrane dramatically alters the cholesterol distribution by mobilizing plasma 
membrane cholesterol for esterification [43, 131], by decreasing sterol 
biosynthesis [43, 132], and by activating the synthesis of steroid hormones in 
steroidogenic cells [133]. The addition of cholesterol to cultured fibroblasts 
inhibits their ASMase activity. Conversely, the loss of ASMase activity leads to 
accumulation not only of sphingomyelin but also cholesterol [134], indicating that 
there is a regulatory mechanism which maintains a fixed ratio of sphingomyelin to 
cholesterol.  Furthermore, the addition of bSMase that hydrolyses the SM at the 
plasma membrane, stimulates cholesterol translocation from the plasma 
membrane to the endoplasmic reticulum where it suppresses cholesterol 
synthesis by inhibiting HMG-CoA reductase [135].  
Overall, it is fairly well established that sphingomyelin and cholesterol 
levels at the plasma membrane are coordinately regulated and affect signaling 
events by re-organizing the signaling domains, e.g. lipid rafts. This may have 
interesting implications for the regulation of TACE activity, since it has already 
been suggested that sequestration of TACE in the sphingomyelin:cholesterol 
rafts is rate-limiting for its activity [120]. 
Recent studies in mice have linked ASMase deficiency to increased 
susceptibility to viral and bacterial infections [55, 56]. ASMase-deficient 
macrophages exhibit a slow rate of elimination of pathogens like L. 
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monocytogenes, alphavirus Sindbis and P. aeruginosa, caused by a protracted 
phago-lysosomal fusion and membrane budding. A defect in the rab4 recycling 
pathway has been identified in asm-/- fibroblasts isolated from patients with 
Niemann-Pick Disease type A [136]. Together these studies suggest that in 
addition to a role in signaling, ASMase might be involved in the regulation of 
membrane fusion by regulating membrane fluidity and/or curvature.  
 
B. Materials and Methods 
 
Materials  
 
Ammonium chloride was purchased from Sigma-Aldrich Co. (St. Louis, 
MO). Fluorogenic Peptide Substrate III and anti-TNF used for 
immunofluorescence came from R&D Systems (Minneapolis, MN). TAPI-1 (N-
(R)-[2-(Hydroxyaminocarbonyl) methyl]-4-methylpentanoyl-L-naphtyl-alanyl-L-
alanine, 2-aminoethyl amide; TNF Protease Inhibitor-1) was from Calbiochem 
(La Jolla, Ca). D-erythro-sphingosine was from Avanti Polar Lipids (Alabaster, 
AL). Anti-EEA1 and anti-TACE antibodies were from Santa Cruz Biotechnology 
(Santa Cruz, CA). 
 
Animals  
 
Litter-matched asm+/+ and asm-/- mice were maintained as described 
earlier (Chapter three, Section B) and used for experiments. 
 
SDS-PAGE and Western blotting 
 
Please refer to Chapter Two, Section B for details in performing SDS-
PAGE and Western blotting. 
 
ELISA 
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 The levels of TNF in the medium from asm+/+ and asm-/- miacrophages 
were determined by ELISA as described in Chapter one, Section B. 
 
TACE activity assay 
 
Macrophages were resuspended in 500l detergent free 25mM Tris (pH 
8.0) and homogenized by passing through a 26G needle several times. A total of 
5-10g protein was incubated with 10M fluorogenic substrate III (Mca-P-L-A-Q-
A-V-Dpa-R-S-S-S-R-NH2) in 25mM Tris, pH 8.0 (100l final volume). The 
fluorescence was analyzed with excitation at 320nm and emission at 405nm. 
 
Indirect Immunofluorescence 
 
Cells were cultured on coverslips and treated as indicated. Fixation was 
performed for 5 min in cold methanol (permeabilized cells) or for 30 min in 3% 
formaldehyde (non-permeabilized cells). After blocking the non-specific binding 
with appropriate serum (2%), the proteins of interest were labeled with anti-TACE 
(1:50), anti-TNF (1:50) or anti-EEA1 (1:100) polyclonal antibodies. The immune 
complexes were visualized with FITC-conjugated goat anti-rabbit IgG or TRITC-
conjugated bovine anti-goat IgG. In the co-localization studies, the primary 
antibodies were added sequentially.  
 
Statistical analysis 
 
Please refer to Chapter Two, Section B. 
 
C. Results 
 
Kinetics of post-translational processing of TNF in primary macrophages 
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 To study the post-translational processing of TNF, the conversion of 
proTNF to sTNF was monitored by Western blotting in primary macrophages 
and RAW264.7 cells. As anticipated, neither proTNF nor sTNF forms were 
detected in non-stimulated peritoneal macrophages from both genotypes (Fig.4.2 
A, and B). Substantial accumulation of sTNF in the medium of LPS-treated 
macrophages was noticeable at 6 hours after stimulation and continued for at 
least 20 hours. The amounts of sTNF were higher in asm-/- than in asm+/+ cells, 
which is in excellent agreement with the differences seen by ELISA. Surprisingly, 
we were not able to detect any proTNF in the cellular lysates (Fig. 4.2A), which 
is indicative that the steady-state levels of proTNF were very low. However, co-
treatment with ammonium chloride, which blocks the activity of many lysosomal 
hydrolyses led to very substantial accumulation of the precursor protein inside 
the cells (Fig. 4.2 D), while having no effect on the levels of sTNF in the 
medium (Fig. 4.2 E). These results are in good agreement with earlier 
observations by other groups [122], indicating that proTNF that is not processed 
by TACE is internalized and degraded in the lysosomes. Our study further 
suggests that at least half of the newly produced proTNF undergoes such 
degradation, based on calculations of the volumes that were loaded. Together, 
these observations support the conclusion that in peritoneal macrophages the 
activity of TACE is the rate-limiting factor in TNF processing and that at least in 
primary macrophages, the lysosomal proteolysis of non-processed TNF is very 
substantial and rapid.  
Similar studies were also conducted in the macrophage cell line, 
RAW264.7. As discussed in chapter 2, LPS treatment induced TNF production, 
which was readily detected in the medium as well as in the cells. In contrast to 
peritoneal macrophages the levels of proTNF in the cells were substantial.  
Importantly, inhibition of ASMase activity by desipramine had only a slight effect 
on proTNF and sTNF (Fig. 4.3 A, B, C). Furthermore, unlike primary 
macrophages, the addition of ammonium chloride to RAW 264.7 cells to block 
lysosomal proteolysis of TNF, did not influence the levels of proTNF detected 
in cell lysates (Fig. 4.3 E). Together, these results indicate that there is a 
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significant difference between primary peritoneal macrophages and RAW264. 7 
cells in the post-translational regulation of TNF production. Apparently, in 
RAW264.7 cells proTNF did not undergo efficient lysosomal proteolysis and its 
levels were not affected by inhibition of lysosomal proteases. Because of these 
differences between primary cells and the cell line, the latter was not used any 
further.  
 
Asm-/- macrophages have higher activity of TACE, which is inhibited by an 
increase in ceramide content of the cells 
 
To test directly whether increased TNF production in asm-/- was caused 
by higher activity of TACE, the latter was measured using fluorogenic substrate 
containing the TNF cleavage site. After identifying the range of linearity for the 
in vitro assay (Fig. 4.4A, and B), the TACE activity was measured in detergent-
free lysates from asm+/+ and asm-/- cells. Both, LPS- and control-treated 
macrophages isolated from asm-/- mice exhibited 2 to 3 fold higher activity as 
compared to their respective counterparts isolated from the asm+/+ mice. These 
differences suggest that ASMase-derived ceramide might be a negative regulator 
of TACE (Fig. 4.4C, and D).  
To test this, the levels of cellular ceramide were elevated by the addition 
of bacterial sphingomyelinase or cell-permeable ceramide analogue, C2-
ceramide, to the cultured cells. Both treatments inhibited TACE activity but 
ceramide-mediated inhibition was more than 80% (Fig. 4.4E, and F). To test 
whether ceramide has a direct effect on TACE activity, it was added directly to 
the assay mixture. No inhibitory effect, however, was observed (Fig. 4.5.A). One 
possible explanation for the differences in ceramide capacity to inhibit TACE in 
cells but not in vitro was that in cells ceramide was metabolized. To test this, two 
ceramide metabolites, sphingosine and dihydroceramide, were used. However, 
these treatments also failed to inhibit TACE (Fig. 4.5. B, C). Together these 
results suggest that ceramide has no direct effect on TACE, but may influence its 
activity by reorganizing the membrane bilayer and/or its intracellular localization. 
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Such sensitivity of TACE to the lipid environment was also indicated by the 
inhibitory effect that the addition of Triton X-100 to the TACE assay mixture had 
on the measured activity (Fig. 4.5 D). To that extent, we also observed 
differences in TACE sub-cellular localization between the two genotypes. While 
in asm+/+ macrophages TACE was localized in a Golgi-like compartment in close 
proximity to the nucleus, in asm-/- cells a uniform and diffused staining was 
observed throughout the cell body (Fig. 4.6 B). Studies using quantitative real-
time PCR revealed that asm-/- cells do not express higher levels of TACE mRNA 
(Fig. 4.6 A), thus excluding the possibility that the genotype-specific difference in 
activity and localization reflected differences in protein expression. 
Surprisingly, TACE activity was not sensitive to stimulation with LPS. 
However, this could be a consequence of the specific assay conditions because 
the endogenous substrate, which is absent in the control-treated cells, but 
abundant in the LPS-treated cells may be an efficient competitor for the 
exogenous substrate during an in vitro assay. 
 
Effects of ASMase deficiency on the sub-cellular distribution of TNF 
 
Apparently, ASMase deficiency affected step(s) in the processing of 
proTNF to the sTNF form. To directly monitor proTNF intracellular trafficking 
to and from the plasma membrane, indirect immunofluorescence was employed. 
This approach allowed the detection of substantial production of TNF inside the 
cells, mostly in ER/Golgi compartment (in permeabilized cells), and an 
accumulation at the plasma membrane (in non-permeabilized cells) in response 
to stimulation with LPS (Fig. 4.7A, and B). However, several apparent differences 
were noticeable in asm-/- macrophages: (i) Seemingly, more TNF was present 
throughout the cytosol, and (ii) TNF-positive vesicular structures were detected 
in a close proximity to the plasma membrane. Co-treatment with TAPI-1, a TACE 
inhibitor, increased the number of these TNF positive vesicles in asm-/- but not 
in asm+/+ cells (Fig. 4.7 A and Fig. 4.8 B). Therefore, these vesicular structures in 
asm-/- cells most likely contained TNF designated for TACE-mediated cleavage. 
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Having in mind that TACE activity was higher in the asm-/- macrophages, the fact 
that TAPI-1 sensitive pool of TNF was present in asm-/- but not in asm+/+ cells 
may indicate that more proTNF molecules were recycled back to the plasma 
membrane and underwent TACE-mediated processing in the asm-/- cells than in 
asm+/+ cells. To test this, cells were stained for EEA1, a marker for early 
endosomes. Notably, asm-/- macrophages had a higher number of early 
endosomes as compared to asm+/+ macrophages (Fig. 4.7 C, and Fig. 4.8 C), 
indicative of more active recycling pathways. To test whether the endosomes are 
indeed as a reservoir of proTNF for plasma membrane recycling, co-localization 
studies were done. More TNF-positive vesicles co-localized with EEA1 in LPS 
treated asm-/- cells as compared to asm+/+ cells (Fig. 4.8A, and B). The number of 
these double-positive vesicles increased in the presence of TAPI-1 only in asm-/- 
cells, but not in asm+/+ cells (Fig. 4.8 D). Treatment with ammonium chloride led 
to a significant increase in both TNF-positive and double-positive cellular 
compartments (Fig. 4.8 D). Importantly, the effects of ammonium chloride were 
more pronounced in the asm+/+ than in asm-/- cells. Together these results 
consistently show that the early endosomes contained proTNF that is salvaged 
from lysosomal proteolysis and is destined for recycling and TACE-mediated 
processing. ASMase activity plays an important role in partitioning proTNF 
between these two pathways.  
 
Effects of exogenous sphingomyelinase on TNF processing 
 
To test whether ASMase and ceramide are directly involved in regulating 
TNF recycling, rescue experiments were done. Asm-/- cells were treated with 
exogenous sphingomyelinase to increase ceramide at the plasma membrane. 
This was sufficient to bring the sTNF level close to those measured in asm+/+ 
cells (Fig. 4.9A, B). Furthermore, sphingomyelinase treatment also significantly 
decreased the number of early endosomes detected in asm-/- cells (Fig. 4.9 C). 
These results not only link SMase and ceramide to early endosomes biogenesis 
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but also reveal a correlation between the number of early endosomes and the 
levels of sTNF released in response to LPS. 
 
Genotype-specific differences in cytokine release in vivo  
 
To determine the effect of ASMase deletion on TNF production in vivo, 
litter-matched asm+/+ and asm-/- mice were injected with saline or LPS (5.8mg/kg 
of body weight). TNF and IL-1 were undetectable in saline-injected mice of 
both genotypes. The administration of LPS led to a sharp increase in serum 
levels of both cytokines. However, in ASMase-deficient mice, serum TNF 
reached concentrations that were 10 to 15 fold higher than those measured in 
sera from asm+/+ mice (Fig. 4.10 A), while the levels of IL-1 (Fig. 4.10 B) and IL-
6 (data not shown) were similar for both genotypes. These data are in agreement 
with the genotype-based differences in TNF secretion observed in isolated 
peritoneal macrophages and indicate that ASMase deficiency has a specific 
effect on the regulation of TNF in vivo. 
 
D. Discussion 
 
The results presented in this chapter provide evidence that ASMase and 
ceramide regulate the rate of post-translational processing and secretion of 
TNF after LPS stimulation.   
Two distinct mechanisms seem to be involved.  First, ASMase-derived 
ceramide apparently functions as a negative regulator of TACE activity. This is 
supported by the inhibition of TACE activity observed after the treatment of 
macrophages with exogenous ceramide or bacterial SMase, both of which 
increase ceramide content of the plasma membrane. Consistently, the intrinsic 
activity of TACE was higher in asm-/- macrophages as compared to asm+/+ cells. 
Most likely, ceramide and ASMase modulate TACE activity by changing the 
membrane microenvironement of the enzyme, because ceramide was effective 
only when added to cultured cells but not directly to the assay mixture. As 
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discussed earlier, TACE is a transmembrane protein and, based on the complete 
loss of activity observed in the presence of detergent, seems to require an intact 
lipid environment for optimal activity. Notably, Tellier et al. found that the mature 
form of TACE, but not the inactive pro-form, is localized in the 
sphingomyelin:cholesterol-rich domains and co-purifies with caveolin 1 and 
flotilin-1. These authors further suggest that sequestration of TACE in the 
sphingomyelin:cholesterol rafts is rate-limiting for its activity [120]. This is in 
excellent agreement with our conclusion that ASMase and ceramide control a 
rate-limiting step in TNF processing. It is of particular interest that treatment 
with SMase that not only hydrolyses SM, thereby depleting the plasma 
membrane of cholesterol, but also has an inhibitory effect of the endogenous 
TACE. It seems likely that the elevated sphingomyelin (and cholesterol) in asm-/- 
cells create a more “favorable” environment for TACE and, consequently, higher 
activity. Second, a seemingly independent mode of regulation was revealed by 
our indirect immunofluorescent studies.  These experiments suggest that 
ASMase also has an affect on the fate of intracellular proTNF in peritoneal 
macrophages. It has been proposed previously that proTNF that is not 
immediately cleaved by TACE is internalized and either degraded in the 
lysosomes or recycled back to the plasma membrane, where it can be utilized for 
TACE-mediated cleavage. Our results strongly support such a scenario and 
provide initial evidence that the partitioning of the non-processed TNF between 
these two pathways is modulated and may have a profound effect on the levels 
of TNF secreted in a response to particular stimulus. 
 Consistent with previous studies implicating ASMase in the dynamics of 
vesicle fusion and fission during endocytosis, we also found that asm-/- 
macrophages have increased the number of early endosomes consistent with a 
defect in the endosome maturation to lysosomes. Furthermore, the increased co-
localization of EEA1 and TNF provides evidence that in the absence of 
ASMase, TNF is sequestered in the early endosomes and likely recycled back 
to the plasma membrane and cleaved by TACE. Evidence for this comes from 
the observation that the inhibition of TACE by TAPI-1 caused significant elevation 
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in intracellular TNF as well as TNF/EEA1 co-localization only in the asm-/- but 
not in asm+/+ cells.  In contrast, in asm+/+ cells similar increases were observed in 
the presence of ammonium chloride, indicating that a portion of intracellular 
TNF, localized in the early endosomes undergoes TACE-mediated cleavage in 
asm-/- cells, but lysosomal clearance in asm+/+ cells.  
Membrane lipids and proteins are moved from the early endosomes back 
to the cell surface via two main routes: the rab4-dependent fast recycling 
pathway, and the rab11-mediated slow recycling pathway. Fibroblasts from 
Niemann-Pick Disease Type A patients seem to lack the rab4-mediated 
recycling, but exhibit a more active rab11-dependent pathway [136]. Therefore, 
the latter could be responsible for the increased TNF recycling in asm-/- cells.   
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Figure 4.1. Post-translational processing of TNF. TNF is initially 
synthesized as 26kD precursor molecule (proTNF). It is selected as a specific 
cargo of trans-Golgi vesicles, which fuse with rab11 recycling endosomes en 
route to the plasma membrane. At the plasma membrane proTNF is cleaved by 
TACE at its ectodomain to release the soluble 17kD mature form (sTNF). The 
uncleaved proTNF is internalized and either degraded in the lysosomes or 
recycled back to the plasma membrane. Abbreviations: TLR4, Toll-like receptor 
4; RE, recycling endosomes; EE, early endosomes; LE, late endosomes. 
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Primary peritoneal macrophages 
  
 
Figure 4.2. Post-translational processing of TNF in primary peritoneal 
macrophages. Peritoneal macrophages were isolated from asm+/+ and asm-/- 
mice and treated with LPS (10ng/ml) for the indicated times in the presence or 
absence of ammonium chloride (10mM). TNF levels were determined in cell 
extracts (A, D) or medium (B, C, and E) by Western Blotting. Cyclophilin A levels 
were used to control for uniform loading. For quantification purposes, the data 
were shown as a ratio of the levels in the medium collected from asm-/- and 
asm+/+ cells and are mean  s.d. of three independent experiments. 
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RAW264.7 cells 
 
 
 
Figure 4.3. Post-translational processing of TNF in RAW264.7 macrophage 
cell line. RAW264.7 cells were stimulated with LPS (10ng/ml) for the indicated 
time in the presence or absence of ammonium chloride (10mM). Where indicated 
pre-treatment with desipramine (25M) was used to inhibit ASMase activity. 
TNF levels were determined in cell extracts (B, C, E) or medium (A, and D) by 
Western Blotting. Cyclophilin A levels were used to control for uniform loading. 
For quantification purposes (C), the data were shown as a percent of the 
maximum response and are mean  s.d. of two independent experiments.  
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Figure 4.4. TACE activity in asm+/+ and asm-/- macrophages. A, B. Test for 
linearity of TACE activity assay with protein and time. TACE activity 
measured in vitro in detergent-free lysates prepared from RAW264.7 cells. C, D. 
Effect of ASMase deficiency on activity of TACE. TACE activity is measured 
in lysates from asm+/+ and asm-/- macrophages in vitro.  Cells were treated with 
saline (C) or LPS (10 ng/ml, D) for 4 hours. Activity is shown as a percent of the 
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maximum value measured in each set of experiments, which were 3907 RFU 
and 3501 RFU for saline- and LPS-treated asm-/- macrophages, respectively. The 
significance of the interaction effect is shown (###, p<0.001) based on two-way 
ANOVA. E-H.  Effect of sphingomyelinase and ceramide on TACE activity.  
asm+/+ (E, G) and asm-/- (F, H) macrophages were treated with LPS (10ng/ml) for 
4 hours in the presence of C2-ceramide (60M) (E, F), vehicle control (0.1% 
ethanol) or bacterial sphingomyelinase (0.1units/ml) (G, H). TACE activity is 
shown as percent of the value measured in vehicle-treated cells.  The data are 
mean  s.d. (n=3) and statistical significance of the treatment is shown (*, 
p<0.05) based on student t-test.  
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Figure 4.5. Effect of sphingolipids and detergent on TACE activity in vitro. 
A-C Effect of Sphingolipids. TACE activity was measured in detergent-free 
lysates from asm+/+ macrophages in the presence of C2-ceramide (A), 
Dihydroceramide (B), and Sphingosine (C) added directly to the reaction mixture 
of TACE activity assay. D. Effect of Detergent. TACE activity was measured in 
lysates from asm+/+ macrophages in the presence (diamond) or absence (circle) 
of Triton X-100. TACE activity is shown as percent of the value measured in 
vehicle-treated cells. 
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Figure 4.6. Expression and sub-cellular localization of TACE. A. TACE 
mRNA levels. Macrophages from asm+/+ and asm-/- mice were isolated and 
treated with LPS (10ng/ml) for the indicated time. TACE mRNA levels were 
determined by real-time PCR and normalized to GAPDH mRNA in the same 
sample.  The Data are presented as mean ± s.e.m. of three independent 
experiments. Statistical significance of the treatment effect is shown (**, P<0.01; 
*. P<0.05) based on two-way ANOVA. B. Visualization of TACE. The 
localization of TACE in permeabilized asm+/+ and asm-/- was visualized using 
antibodies against mouse TACE and fluorescent microscopy.  Representative 
image of three independent experiments is shown. Hoechst 33258 was used for 
staining the nuclei. Scale bar represents 20m. 
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Figure 4.7. Sub-cellular localization of TNF in asm+/+ and asm-/- 
macrophages. Macrophages from asm+/+ and asm-/- mice were isolated and 
treated with LPS (10ng/ml) in the presence and absence of TAPI-1 (20M) and 
NH4Cl (10mM) for 4 hours. TNF was visualized in permeabilized (A) and non-
permeabilized (B) cells using antibodies against TNF and confocal microscopy. 
The arrows indicate TNF-positive vesicles proximal to the plasma membrane 
that are visible in asm-/- cells. Antibodies against the endosomal marker EEA1 
were used to visualize early endosomes (C). Western blot analyses of the cell 
culture medium that demonstrate the efficiency of the inhibitors (D). Transmitted 
light images (B, C) show cells morphology. The scale bar represents 10m. 
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Figure 4.8.  Co-localization of TNF and EEA1 in asm+/+ and asm-/- 
macrophages. Peritoneal asm+/+ and asm-/- macrophages were treated with LPS 
(10ng/ml) for 4 hours. Permeabilized cells were probed sequentially for TNF 
(red) and EEA1 (green). Images were collected using confocal microscopy and 
merged (yellow). Only merged images are shown and the TNF/EEA1 co-
localization in a single cell for each panel is depicted by arrows. For 
quantification purposes, the bulk fluorescence visible in the center of each cell 
was excluded and the number of TNF (B)-, EEA1(C)- and double (D)-positive 
vesicles (size bigger than 4 pixels) was counted in 10 cells of each slide.  Data 
shown are average  s.e.m. Statistical significance of the main effect (***<0.001; 
**<0.01; *<0.05) and interaction effect (### < 0.001) was determined by two-way 
ANOVA. The scale bar represents 20m. 
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Figure 4.9. Effect of exogenous sphingomyelinase on sTNF and EEA1 in 
asm-/- macrophages. Elicited peritoneal macrophages from asm+/+ and asm-/- 
mice were treated for 4 hours with 10ng/ml LPS alone or in combination with 
0.1units/ml bacterial sphingomyelinase. A.  Levels of TNF in medium based 
on Western blotting. B. Quantification of sTNF in the medium. The graph 
represents the mean values  s.d. of intensity of TNF bands from three 
independent experiments. C. Visualization of the early endosomes.  
Immunofluorescent images depicting EEA1-positive early endosomes (green) in 
permeabilized macrophages. Statistical significance of the main effect (**, 
P<0.01) and the interaction effect of the treatment and the genotype (#, P<0.05) 
are shown based on two-way ANOVA. 
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Figure 4.10. Cytokine levels in LPS-injected asm+/+ and asm-/- mice.  
Mice were injected i.p. with LPS (5.8mg/kg body weight) or saline. Serum was 
collected at the indicated times and the levels of TNF (A) and IL-1 (B) were 
measured by ELISA. Data for LPS-injected asm+/+ (filled circles) and asm-/- (open 
circles) are shown.  The levels of the cytokines in saline-injected animals were 
below the detection levels. Data for individual animals are shown and are the 
average of identical measurements done in triplicates. The group average  
s.e.m. is shown on the side. The significance of the main effects of genotype and 
LPS (***, P<0.001; **, P<0.01; *, P<0.05) and the interaction effect (###, 
P<0.001) is based on two-way ANOVA with Bonferroni post-test analysis.  The 
inserts are representation of the data from asm+/+ mice on a smaller scale. 
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CHAPTER FIVE 
 
Conclusion 
 
A. Summary of findings 
 
This study provides evidence that ASMase and ceramide act as negative 
regulators of LPS-induced TNF secretion both in vivo and in vitro.  
Studies in isolated peritoneal macrophages showed that in ASMase 
deficient cells LPS induced up to 3 fold higher levels of sTNF compared to the 
control cells. Exogenous ceramide was sufficient to suppress TNF secretion 
confirming the specificity of this effect.  
Further mechanistic investigations in peritoneal macrophages as well as in 
RAW264.7 macrophage cell line revealed that ASMase deficiency does not affect 
the rate of IRAK-1 degradation and the activation pattern of ERK and JNK. 
Moreover, the steady-state levels of TNF mRNA were not influenced by 
ceramide or the lack of ASMase activity. Altogether, these results indicate that 
ASMase affects step(s) of TNF production downstream of mRNA synthesis.  
Detailed studies on the post-translational regulation of TNF secretion 
further revealed that in macrophages post-translational processing is a major 
determinant of the amount of sTNF secreted in response to LPS. Importantly, 
for the first time it was demonstrated that a substantial amount of proTNF 
undergoes proteolysis in an acidic compartment, most likely lysosomes, since 
treatment with the lysosomotropic agent ammonium chloride caused a dramatic 
acumulatin of proTNF in the cells. These results further suggest that the activity 
of TACE is rate-limiting for the production of sTNF and is likely under tight 
regulation. 
Indeed, ASMase and ceramide seem to affect the cleavage of proTNF to 
the bioactive mature form, sTNF, by acting as negative regulators of TACE 
activity. Similarly to the effect on TNF secretion, ASMase deficiency was linked 
to 3 fold increase in TACE activity and this effect was abolished after treatment 
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with exogenous ceramide or bSMase. The exact mechanism by which ASMase 
regulates TACE activity is not yet determined, however it seems likely that the 
effect is on the localization of TACE rather than direct inhibition by ceramide.  
An additional role of ASMase in the post-translational regulation of TNF 
was also suggested by studies using indirect immunofluorescent: compared to 
the control cells, in ASMase deficient macrophages more of the internalized 
proTNF co-localizes with early endosomes. This genotype-based difference in 
co-localization of TNF and EEA1 is exacerbated by the inhibition of TACE 
mediated proTNF cleavage, but disappears after the addition of ammonium 
chloride to block the lysosomal proteolisis of proTNF. Therefore, one plausible 
interpretation of these results is that in asm-/- cells the lysosomal proteolysis of 
TNF occurs at a slower rate compared to the asm+/+ cells, and instead proTNF 
is redirected to the recycling pathway and delivered to the plasma membrane 
where it can be re-used as a substrate for TACE and released as sTNF in the 
medium. Such a scenario is in agreement with the detected higher TACE activity 
in asm-/- cells, and explainsthe  increased secretion of sTNF despite the lack of 
genotype-based differences at the level of TNF mRNA. 
It is unclear which of the two forms of ASMase is implicated in this 
phenomenon. While the secretory form might be responsible for the regulation of 
TACE activity at the plasma membrane, the lysosomal form might be linked to 
the defects in endosomal maturation (Fig. 5.1.).  
Finally, the parallel use of primary peritoneal macrophages and 
RAW264.7 cell line throughout this study demonstrated that: (i) both cell models 
responded to LPS stimulation in a similar fashion with regards to the activation of 
MAP kinases and synthesis of TNF mRNA, however (ii) they differ substantially 
in the post-translational processing of TNF, which might be a result of a 
different rate of lysosomal proteolysis of uncleaved TNF. Therefore, RAW264.7 
cells may not be a physiologically relevant model to study the mechanisms of 
TNF post-translational regulation.  
 
B. Future directions 
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To decipher the mechanisms by which ASMase influences TACE activity 
 
It has been demonstrated that ASMase and ceramide affect TACE activity, 
thus it is of great interest to provide additional details regarding the mechanism 
by which they exert their effects. The existing data suggest that the increased 
activity in ASMase deficient cells is not a consequence of higher level of TACE 
expression and most likely ceramide does not directly inhibit the enzyme. 
However, the difference in the localization of TACE between genotypes and the 
requirement of an intact membrane for optimal activity of TACE suggest that lipid 
composition and distribution at the plasma membrane in asm-/- macrophages 
may create more favorable environment for TACE activity. This hypothesis can 
be tested initially by in situ TACE activity assay where the intact cell membranes 
will be preserved and will reflect the differences in TACE activity found between 
asm-/- and asm+/+ cells. Furthermore, in situ assay performed after cell treatment 
with sphingomyelinase or cholesterol depleting agents will provide additional 
insight about the role of sphingomylin:cholsterol enriched lipid domains for TACE 
activity. A direct link between the increase in TACE activity and its localization 
within lipid rafts can be established by the isolation of sphingomyelin:cholesterol 
rich microdomains and measurement of TACE activity in rafts and non-rafts 
fractions. The distribution of TACE within rafts and non-rafts fractions can be also 
visualized in macrophages from asm+/+ and asm-/-  mice by  Western blotting .  
Translocation of TACE within or out of lipid rafts has been suggested to 
play a role in substrate selectivity. TNF is not the only substrate for TACE, 
therefore it is of importance to determine whether the role of ASMase is limited to 
TACE-mediated cleavage of TNF, or it if is a broader phenomenon and holds 
true for other substrates as well. A number of studies implicate TACE in the 
shedding of TGF, therefore measuring the levels of TGF in medium from asm-
/- and asm+/+ will provide some insight about the effect of ASMase on substrate 
selectivity of TACE.  
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Investigate in further details the role of ASMase in determining the fate of 
internalized proTNF 
 
Another question to be addressed is the effect of ASMase deficiency on 
the distribution of internalized TNF in cellular compartments involved in the 
pathways for recycling and degradation. Evidence was provided that after 
inhibition of TACE-mediated cleavage in asm-/- macrophages more TNF co-
localizes with the marker for early endosome. This result together with the finding 
that asm-/- have higher amount of early endosomes indicates that in ASMase 
deficient cells the maturation of early endosomes to late endosomes and 
lysosomes may be impaired and less TNF is subjected to lysosomal proteolysis. 
Experiments for co-localization of TNF with markers of late endosomes and 
lysosomes will provide further support for this hypothesis. Additionally, it is also 
important to provide direct evidence that ASMase deficiency is linked to an 
increased rate of TNF recycling to the plasma membrane and that internalized 
and recycled proTNF is used for cleavage by TACE. Therefore, it is essential to 
demonstrate increased co-localization of TNF with rab11 recycling vesicles in 
macrophages from asm-/- cells compared to asm+/+ cells. To establish a direct link 
between the rate of the recycling pathway and the amount of sTNF secreted in 
the medium, studies with an overexpression of wild-type rab11 or dominant 
negative form can be performed followed by Western blotting or ELISA to monitor 
sTNF in the medium.  
 
Physiological significance of the negative regulation of TNF production by 
ASMase and ceramide
 
The diverse nature of pathogens and the enormous number of proteins 
engaged in the host defense will lead to overwhelming immune response if it 
were left unchecked. Therefore, TLR4 signaling is under tight negative 
regulation, which is achieved at multiple levels and some key players have been 
already identified. During acute bacterial infection the effective concentration of 
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LPS is lowered after binding to the soluble TLR4, which appears to serve as 
decoy receptor and prevents the interaction between TLR4 and other co-receptor 
complexes, especially CD14 and MD-2, and will therefore terminate TLR4 
signaling. However, once the interaction between cell surface TLR4 and LPS has 
occurred, TLR4 signaling can be controlled by intracellular regulators. The 
recruitment of a shorter version of MyD88 (MyD88s) ends the signal at the level 
of TLR4 associated adaptor proteins [137]. Overexpression of MyD88s favors 
formation of MyD88s-MyD88 heterodimers, in the presence of which IRAK-1 is 
recruited but not phosphorylated [138]. Interestingly, MyD88s is inhibitory in 
respect to NF-B signaling, but its overexpression does not prevent AP-1 
activation, suggesting that it is important for the fine-tuning of TLR4 responses 
[139]. Another candidate for negative regulator of TLR4 signaling is IRAKM, 
which is induced by LPS and knockout mice for this molecule have enhanced 
production of pro-inflammatory cytokines after stimulation with LPS. Similarly, 
SOCS-1 deficient mice produce high levels of pro-inflammatory cytokines and 
are highly susceptible to septic shock, suggesting that SOCS-1 is an important 
player in negative feedback mechanism for regulation of TLR4-induced 
responses. Interestingly, however, in none of the above mentioned examples has 
the exact mechanisms by which these negative regulation occurs been fully 
elucidated. It appears that some of the intracellular regulators are present 
constitutively to control TLR4 activation at a physiological level, whereas others 
are upregulated by TLR4 signaling during infection to attenuate the TLR4 
response in a negative feedback loop. ASMase appears to fulfill the requirements 
of the second type of negative regulators; (i) LPS stimulation leads to activation 
of ASMase and generation of ceramide, (ii) a hallmark of the immune response 
to LPS is TNF production, which in turn exerts strong pro-apoptotic effects on 
various cell types, and (iii) TNF induced apoptosis is mediated by ASMase-
derived ceramide. Uncontrolled production of TNF clearly has deleterious 
effects for the organism and is linked to high morbidity and mortality during septic 
shock. Therefore, it is tempting to speculate that ASMase might serve as a 
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sensor and it is a component of a negative feedback mechanism for regulation of 
TNF levels.  
Both forms of ASMase, secretory and lysosomal, are altered during the 
onset of various diseases including cancer, obesity, and septic shock. One could 
speculate that cellular ASMase activity and/or ceramide content might have a 
more important role in regulating systemic inflammatory responses than 
previously thought by affecting the magnitude of TNF release by the cells of the 
immune system and other TNF-producing cells. Such a conclusion is supported 
by studies demonstrating that patients with Niemann-Pick Disease are at high 
risk of developing atherosclerosis, an inflammatory disease with a clear link to 
TNF levels. 
A variety of TACE substrates have been described with a broad spectrum 
of biological activities; so the role of ASMase on TACE activity may not be limited 
to TNF secretion and may have additional importance since the differential 
regulation of TACE expression and activity has been demonstrated in conditions 
such as cancer and cardiovascular disease. For example, an increase in TACE 
expression has been found in breast cancer, ovarian carcinomas, and prostatic 
carcinomas; and it was suggested to play an important role in tumor progression 
via activation of HER4 ligands [140]. Furthermore, it has been shown that 
activation of EGFR signaling during breast cancer progression was driven by 
TACE [141]. Targeting TACE activity has been considered as a promising 
therapeutic target in colorectal cancer [142]. Furthermore, abnormal TACE 
activity has also been reported in cardiovascular diseases. For example, a 
possible role of TACE on vascular complications of diabetes has been suggested 
[143] and polymorphism of the TACE gene is linked to an increased risk of 
cardiovascular death [144].
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Figure 5.1. Proposed mechanism for the role of ASMase in LPS-induced 
TNF production.  
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